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The landmark discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka has transformed
regenerative biology. Previously, insights into the pathogenesis of chronic human diseases have been hin-
dered by the inaccessibility of patient samples. However, scientists are now able to convert patient fibro-
blasts into iPSCs and differentiate them into disease-relevant cell types. This ability opens new avenues
for investigating disease pathogenesis and designing novel treatments. In this review, we highlight the
uses of human iPSCs to uncover the underlying causes and pathological consequences of diabetes and
metabolic syndromes,multifactorial diseaseswhose etiologies have been difficult to unravel using traditional
methodologies.Types of Diabetes and Metabolic Syndromes
Diabetes is a multifaceted, multifactorial disease whereby the
body is unable to secrete adequate amounts of biologically
active insulin to maintain euglycemia. Clinical diagnosis of dia-
betes is evident when a patient exhibits persistent hyperglyce-
mia (fasting blood glucose is R 7.0 mM or 126 mg/dl, blood
glucose level 2 hr after a glucose load [oral glucose tolerance
test; OGTT] isR 11.1 mM or 200 mg/dl, or glycated hemoglobin
[HbA1c] is R 6.5%). There are various types of diabetes and
metabolic syndromes that can bemodeled using induced plurip-
otent stem cells (iPSCs). These can be categorized into mono-
genic forms (maturity onset diabetes of the young [MODY],
neonatal diabetes [Steck and Winter, 2011], mitochondrial dia-
betes, and syndromes of insulin resistance [Doria et al., 2008]),
type 1 diabetes (T1D), and type 2 diabetes (T2D) (Figure 1).
Each of these subtypes is briefly discussed.
Maturity Onset Diabetes of the Young
MODY is characterized by early (<25 years of age) onset of non-
ketotic, noninsulin-dependent diabetes and commonly presents
as mild, asymptomatic hyperglycemia (fasting blood glucose
6–7mMor 108–126mg/dl), although some patients have varying
degrees of glucose intolerance (OGTT blood glucose 7.8–11mM
or 140–198 mg/dl; seldom >11.1 mM or 200 mg/dl), which
develops into persistent fasting hyperglycemia. MODY exhibits
an autosomal-dominant mode of inheritance, and thus only
one copy of the abnormal gene from either parent is required
for the inheritance (Fajans et al., 2001). To date, 11 MODYs
have been described (Table S1), and MODY1–MODY5 are rela-
tively better understood. Although most MODYs result from
heterozygous mutations, homozygous mutations have been
identified for MODY2 and MODY4 genes (Njølstad et al., 2001;
Stoffers et al., 1997).
MODY1 occurs as a result of a mutation in the hepatocyte
nuclear factor 4 alpha gene (HNF4A) (Yamagata et al., 1996a),
and patients are characterized by hyperglycemia after an
OGTT as compared to MODY2 (Pearson et al., 2001). Theydevelop progressive hyperglycemia and commonly require oral
hypoglycemic medications or even insulin (Fajans et al., 2001).
MODY2 is the firstMODY to bedescribed (Froguel et al., 1993).
Homozygous mutations in the glucokinase gene (GCK) result in
permanent neonatal diabetes due to complete GCK deficiency,
whereas heterozygous mutations result in MODY2 (Osbak
et al., 2009). To date, more than 100 mutations have been found
in GCK, and all result in a similar phenotype (Miller et al., 1999).
HeterozygousGCKmutations often result inmild nonprogressive
hyperglycemia (fasting blood glucose 6.1–8.1 mM or 110–
145 mg/dl), which responds to diet therapy (Pearson et al.,
2001). Impaired glucose tolerance in MODY2 patients can be
detected even at birth, and insulin levels are usually normal.
Eventually, less than 50% of MODY2 patients present overt dia-
betes. Patients with MODY2 have a lower prevalence of diabetic
microvascular complications as compared to other MODYs.
MODY3 (Yamagata et al., 1996b) is the most common MODY,
withmore than 120mutations identified to date in the hepatocyte
nuclear factor 1 alpha gene (HNF1A) (Fajans et al., 2001). Similar
to MODY1, MODY3 patients develop hyperglycemia, which
deteriorates over time. In some instances, patients may be sen-
sitive to oral hypoglycemics (sulfonylureas) (Søvik et al., 1998).
Ultimately, 40% of these patients require insulin (Fajans
et al., 2001). MODY3 is relatively serious compared to other
MODYs because of a high frequency of diabetic complications
(Fajans et al., 2001; Isomaa et al., 1998).
MODY4 (Stoffers et al., 1997) patients who are heterozygous
for mutations in the pancreatic and duodenal homeobox 1 gene
(PDX1) exhibit a severe impairment of insulin secretion and thus
hyperglycemia (fasting blood glucose 9.2 mM or 165 mg/dl)
(Clocquet et al., 2000). However, diabetes may develop at a later
age as compared to otherMODY patients. Some patients can be
treated with oral sulfonylureas, while others require insulin.
MODY5 patients manifest mutations in the hepatocyte nuclear
factor 1 beta gene (HNF1B) (Horikawa et al., 1997) and
commonly exhibit a low birth weight. Dorsal pancreatic agenesisCell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 775
Figure 1. Types of Diabetes and Metabolic Syndromes
The various types of diabetes and metabolic syndromes that can be modeled
using induced pluripotent stem cells (iPSCs) include monogenic forms of
diabetes, type 1 diabetes (T1D), and type 2 diabetes (T2D). T1D occurs as a
result of immune attack by immune cells, such as macrophages and T cells,
whereas T2D occurs as a result of insulin resistance in the pancreas, muscle,
fat, and liver. Square represents male subjects, whereas circle represents
female subjects. Filled symbols denote subjects with diabetes.
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Besides diabetes, MODY5 patients exhibit severe nondiabetic
renal dysfunction (Bingham et al., 2001). Given that hypoplastic
glomerulocystic kidney disease can be diagnosed before
glucose intolerance and diabetes occurs in these patients, it is
likely that the kidney disease develops independent of the dia-
betic state. Renal dysfunction can occur as a result of renal
cyst formation (Bingham et al., 2001), impaired creatinine clear-
ance (<80–120 ml/min; due to compromised glomerular filtra-
tion), proteinuria, and chronic renal failure (Horikawa et al., 1997).
Several rare types of MODYs, including MODY6 (NEUROD1)
(Malecki et al., 1999), MODY7 (KLF11) (Neve et al., 2005),
MODY8 (CEL) (Raeder et al., 2006), MODY9 (PAX4) (Plengvidhya
et al., 2007), MODY10 (INS) (Molven et al., 2008), and MODY11
(BLK) (Borowiec et al., 2009), have been reported, and their fea-
tures are briefly tabulated in Table S1.
Neonatal Diabetes
Besides MODY, neonatal diabetes is the other main form of
monogenic diabetes (Table S2) and occurs in the first 6 months
of life (Aguilar-Bryan and Bryan, 2008). It is diagnosed when
infants exhibit persistent hyperglycemia (blood glucose776 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.> 8.3–11.1 mM or 150–200 mg/dl) due to insufficient insulin pro-
duction, leading to ketoacidosis (an excess of acid in the body).
Permanent and transient neonatal diabetes each make up 50%
of the cases.
Permanent neonatal diabetes is more commonly caused by
mutations in the ATP-sensitive potassium channel: KCNJ11
(KIR6.2) and ABCC8 (SUR1) (Edghill et al., 2010) and insulin
gene (INS) (Støy et al., 2010). Infants withKCNJ11mutations pre-
sent clear correlations between genotype and phenotype
compared to those with ABCC8 mutations (Edghill et al.,
2010). Infants with KCNJ11 and ABCC8 mutations can be
treated with oral sulfonylureas (Pearson et al., 2006). Interest-
ingly, some patients with KCNJ11 mutations also develop a
neurologic condition called DEND syndrome (developmental
delay, epilepsy, and neonatal diabetes). Transient neonatal dia-
betes is primarily caused by mutations and/or defects in ZAC/
HYMAI (6q24) (Mackay and Temple, 2010). Diabetes occurs in
the first 6 weeks of life, resolves by 18 months, may recur, and
usually requires insulin treatment.
It should be noted that patients with neonatal diabetes may
suffer from secondary complications, such as diabetic ketoaci-
dosis and hypoglycemia, and over time retinopathy and ne-
phropathy may also develop. Other less common mutations
that lead to neonatal diabetes are highlighted in Table S2.
Mitochondrial Diabetes
Mitochondrial DNA (mtDNA), which makes up 3%–5% of
human cellular DNA, encodes transfer RNAs (tRNAs) and several
metabolic enzymes. Often, mtDNA accumulate mutations with
time, leading to diabetes. The most common mutation linked
to diabetes is 3242A > G in the MT-TL1 gene, which encodes
tRNALeu(UUR) (Maassen et al., 2005). Mitochondrial mutations
are maternally inherited and are commonly associated with
neurosensory hearing impairment. The syndromes related to
diabetes are maternally inherited diabetes and deafness
(MIDD) (Maassen et al., 2005) and mitochondrial encephalopa-
thy, lactic acidosis, and stroke-like episodes (MELAS) (Sproule
and Kaufmann, 2008). MELAS has a broad range of clinical man-
ifestations and requires early treatment with insulin.
Syndromes of Insulin Resistance
Insulin resistance is a common feature of both obesity and type 2
diabetes (Petersen and Shulman, 2006). Here, monogenic de-
fects in the insulin signaling pathway, lipoatrophic diabetes,
andmonogenic forms of obesity, all of which lead to insulin resis-
tance, will be discussed (Tsigos et al., 2002).
Monogenic Defects in Insulin Signaling Pathway. Insulin can be
defective at two levels: the proinsulin or insulin gene. Impaired
processing of proinsulin (R65H) results in familial hyperproinsuli-
nemia (Gruppuso et al., 1984). High circulating levels of proinsu-
lin affects glucose homeostasis, resulting in mild to moderate
diabetes. Mutations in INS can also cause diabetes (Steiner
et al., 1990). Patients present with high circulating levels of insu-
lin due to increased insulin half-life and reduced receptor-medi-
ated insulin clearance. Many INS mutations are heterozygous,
and there is only a mild impact on glucose homeostasis.
Defects in the insulin receptor can lead to extreme insulin
resistance (Taylor, 1992). Syndromes of insulin resistance
include Donohue syndrome, type A insulin resistance syndrome,
and Rabson-Mendenhall syndrome (Semple et al., 2011). Dono-
hue syndrome is the most severe form of insulin resistance
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gous mutations. Patients with these mutations manifest devel-
opmental abnormalities, including intrauterine and neonatal
growth retardation. A high rate of early death occurs during in-
fancy or in children less than 2 years of age. Type A syndrome
of insulin resistance and Rabson-Mendenhall syndrome are usu-
ally caused by heterozygousmutations, and the patients present
with severe insulin resistance, acanthosis nigricans, and hyper-
androgenization with polycystic ovarian disease. Hyperandro-
genism occurs due to hyperinsulinemia and insulin resistance
(Semple et al., 2011).
Other Monogenic Forms of Insulin Resistance Resulting in Lipoa-
trophic Diabetes. Besides defects in the insulin signaling
pathway, monogenic defects in several other genes also result
in insulin resistance (Hegele, 2003). Many of these mutations
result in obesity, but the severe insulin resistance is not caused
by obesity. Mutations in nuclear membrane protein LMNA (lamin
A/C) (Shackleton et al., 2000) and peroxisome proliferator-acti-
vated receptor gamma (PPARg) cause familial partial lipodystro-
phy, and mutations in AGPAT2 (1-acylglyerol-3-phosphate
O-acyltransferase) and seipin (BSCL2) (Magre´ et al., 2001) cause
congenital generalized lipodystrophy.
Monogenic Forms of Obesity. Genes involved in genetically
determined obesity include leptin (LEP), leptin receptor (LEPR),
proopiomelanocortin (POMC), prohormone convertase 1 (PC1),
and the MC4 receptor (MC4R). Mutations in these genes affect
neurological behavior, appetite, and satiety control, leading to
a predisposition to obesity. Leptin signaling is important for the
regulation of energy homeostasis. Patients with congenital leptin
deficiency due to DG133 frameshift mutation (Montague et al.,
1997) respond to leptin therapy. A leptin receptor mutation has
also been reported (Cle´ment et al., 1998). Although mutations
in LEP or LEPR have been reported, the more common defect
in leptin metabolism occurs as a result of leptin resistance, which
is still poorly understood.
In the hypothalamus, leptin activates catabolic POMC and
switches off anabolic neuropeptide Y and agouti-related protein
neurons. A loss-of-function mutation in catabolic POMC, which
possibly acts as a dietary fat sensor, thus results in obesity
(Krude et al., 1998). PC1 is also important for energy homeosta-
sis in humans, and a heterozygote for PC1 has been reported
(Jackson et al., 1997). MC4R is a G protein-coupled receptor
for two peptide derivatives of POMC (a- and b-melanocyte-stim-
ulating hormone, MSH) that are synthesized in the hypothala-
mus. Patients with MC4R mutation have increased fat and lean
mass. Accordingly, mutations in MC4R are quite common as
compared to other human monogenic diseases (Farooqi et al.,
2003) and commonly result in haploinsufficiency.
Type 1 Diabetes
Type 1 diabetes (T1D) accounts for 5%–15% of all diabetes
cases, can occur at any age, and is common before the age of
40. T1D occurs when pancreatic b cells are destroyed by an
autoimmune response in the presence of autoantigens, such
as insulin, ZnT8, GAD65, IA-2 (Winter and Schatz, 2011), and
others, thereby leading to absolute insulin deficiency (van Belle
et al., 2011). T1D is a complex disease resulting from both
genetic predisposition and environmental triggers. The autoim-
mune attack may be triggered by environmental factors, such
as diet, which affects the intestinal microbiome (Mathis and Be-noist, 2012), and viral infections (Coppieters et al., 2012) in peo-
ple who are genetically predisposed (Baker and Steck, 2011).
Lack of insulin (little or none) in T1D disturbs glucose homeosta-
sis and results in ketoacidosis. The constant exposure to hyper-
glycemia contributes to complications such as neuropathy,
ischemic stroke, retinopathy, diabetic foot ulcer, cardiovascular
disease, and nephropathy. There is an absolute requirement for
daily insulin injections in T1D patients.
Type 2 Diabetes
Type 2 diabetes (T2D) accounts for 85%–95% of patients with
diabetes. It usually occurs after the age of 40when the peripheral
tissues (skeletal muscle, adipose, and liver) are unable to
respond to insulin normally, a condition known as insulin resis-
tance. In addition, pancreatic b cells are unable to respond to
glucose stimulation and manifest defects in secretion (b cell
dysfunction) (Kahn, 1994), leading to a relative insulin deficiency.
Insulin resistance (commonly caused by obesity) (Petersen and
Shulman, 2006) often occurs before glucose intolerance is
detectable (Martin et al., 1992). By the time diabetes is diag-
nosed, more than 80% of pancreatic b cells have failed. T2D is
a complex disease arising from complicated interactions
between genetics (probably multiple genes) and environmental
factors (obesity, diet, lack of exercise) (Franks, 2011). It is often
associated with obesity and is the most common metabolic dis-
order. Some genes that have been reported to be involved in T2D
include insulin-receptor substrate-1 (IRS-1), glycogen synthase,
glucagon receptor, ras-related protein associated with diabetes
(RAD), histocompatibility antigens HLA locus-DR4, glycoprotein
PC-1, and intestinal fatty acid binding protein (Kahn et al., 1996).
Treatments include exercise, dietary changes, oral antidiabetic
medications, and insulin injections.
Diabetic Complications
Diabetes is a severe chronic disease that has a widespread
impact on health. Often, patients with diabetes suffer from
numerous comorbidities, collectively termed diabetic complica-
tions. Chronic hyperglycemia in these patients results in debili-
tating neuropathy, ischemic stroke, retinopathy, diabetic foot
ulcer, cardiovascular diseases, and nephropathy.
Diabetic neuropathy is caused by an imbalance in metabolites
of glucose and lipids (Vincent et al., 2011). Peripheral sensory
neurons are damaged, resulting in abnormal or loss of sensation.
Patients with diabetes have twice the risk of developing ischemic
stroke, and the hyperglycemia possibly affects recanalization
after ischemic damage (Luitse et al., 2012). Diabetic retinopathy
occurs as a result of microvascular complications in the retina
and appears to be partly mediated by vascular endothelial
growth factor (VEGF) (Abbate et al., 2011). Laser surgery is
commonly required to retard disease progression (Antonetti
et al., 2012). Diabetic foot ulcer occurs partly due to damaged
nerves. Diabetic neuropathy is correlated with muscle weak-
ness. Eventually, muscle atrophy occurs, and the increased
skin pressure results in foot ulcers (Andersen, 2012). Macro-
and microvascular diabetic complications also impede wound
healing, which often results in gangrene and amputations as
well as an economic burden on society.
Cardiovascular disease risk doubles in patients with diabetes,
and the defects include diabetic cardiomyopathy, leading to
heart failure (Dhingra and Vasan, 2012), and atheroscleroticCell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 777
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(Bornfeldt and Tabas, 2011). Diabetic nephropathy is the most
common cause of end-stage renal disease (ESRD). One hypoth-
esis for how diabetes results in nephropathy posits that the stim-
ulation of tubular growth and supranormal glomerular filtration
rate (GFR) leads to injury and nephropathy (Vallon and Thomson,
2012).
Classical Strategies and Challenges for Studying
Mechanisms Underlying Human Diabetes
Traditionally, approaches for investigating themolecular mecha-
nisms underlying human diabetes have ranged from the popular
use of naturally occurring and genetically engineered rodent
models to population-based human genetics studies to small-
scale cell explants obtained fromdiabetic patients. Each of these
strategies will be briefly discussed.
Rodent Models of Diabetes
Diabetic animal models have been widely used to study human
diabetes (King, 2012; Kulkarni and Zisman, 2003). This ranges
from transgenic mice for MODY to the well-studied nonobese
diabetic (NOD) mouse for T1D (Driver et al., 2011). Rodent
models have also been used to study T2D (Lee and Cox,
2011). An alternative type of rodent model involves experimental
induction, including the use of streptozotocin (STZ), alloxan, par-
tial pancreatectomy, and diet-induced obesity (DIO) (Islam and
Loots, 2009). Different rodent strains have been used in exercise
physiology to study effects on obesity and diabetes (Ghosh
et al., 2010). Obesity and hyperinsulinemia have also been
modeledwith animals, including the obese Zucker rat, spontane-
ously hypertensive rat (SHR), the Koletsky rats (obese SHR), the
Goto-Kakisaki (GK) rat, and the Wistar Ottawa Karlsburg W rats
(Aleixandre de Artin˜ano and Miguel Castro, 2009).
In general, the inbred Bio-Breeding Zucker diabetic rat
(BBZDR)/Wor rat has been used to study diabetic complica-
tions (Tirabassi et al., 2004). Other rodent models have also
been developed to study diabetic retinopathy (DR) (Robinson
et al., 2012), diabetic cardiomyopathy (Bugger and Abel,
2009), and atherosclerotic CAD (Wu and Huan, 2007). Trans-
genic animals and the db/db mice have been used to study dia-
betic nephropathy (DN) (Brosius et al., 2009). The Akita and
OVE26 mice, which exhibit T1D, Black and Tan BRachyury
(BTBR) ob/ob mice with T2D, and two mouse models that
lack endothelial nitric oxide synthase (eNOS) are among the
well-studied models that replicate late stages of DN (Alpers
and Hudkins, 2011).
Although rodents have been extensively used to study meta-
bolic disease, and while considerable advances have been
made to understand their pathophysiology, several limitations
are evident. For example, the genetic background of mice plays
a role in modifying the outcome of a phenotype, even when the
same mutation is expressed in mice with different genetic back-
grounds. Further, rodent models do not fully recapitulate the dis-
ease phenotype present in humans. This is exemplified by the
lack of a suitable rodent model that can replicate all stages of
DN. It is also known that studies from rodents do not always
translate to humans. In an attempt to overcome this barrier, hu-
manized mice have been generated to study T1D (King et al.,
2008). Nonhuman primates are also potentially suitable models
for diabetes research, as they may replicate (additional studies778 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.required to substantiate this claim) the pathology in humans
(Harwood et al., 2012). However, the recent focus on limiting an-
imal usage for research precludes this as a viable alternative.
Human Genetics Studies
Human genetics studies in the 1990s first involved genome-wide
linkage studies. The human genome project in the 20th century
then mapped the whole human genome and began the era of
genome-wide association studies (GWASs). Analysis of SNPs
aimed to understand how genetic variations among different in-
dividuals contribute to susceptibility toward a disease such as
diabetes (Collins and Mansoura, 2001). However, to date, it
has been difficult to ascribe a single variant that can fully
account for the pathophysiology of T2D (Barker et al., 2012).
GWASs are currently limited in their ability to identify variants
in genes that are strongly associated with diabetes and meta-
bolic disorders. Thus, it is not as straightforward to translate
these studies and pinpoint genetic determinants of diabetes
(Visscher et al., 2012). More recent high-throughput ‘‘-omics’’
data gave rise to systems biology, which is also proving to be
limited for analyses and interpretation due to the complex bio-
logical networks that regulate mammalian physiology. In sum-
mary, human genetic studies to date have been informative
but do not provide a complete understanding of the mecha-
nisms underlying these complex disorders (Doria et al., 2008;
Polychronakos and Li, 2011).
Cell Explants
One approach to directly study human diabetes has been to
isolate primary cells from subjects and study their properties
in vitro. Thus, fibroblasts from skin biopsies have been derived
from both diabetic and normal patients to determine the mecha-
nisms underlying DN (Millioni et al., 2012). However, it is still
uncertain whether physiological changes observed in skin fibro-
blasts truly mimic those occurring in renal fibroblasts. Lympho-
blasts have also been obtained from diabetic patients with DN
(Davies et al., 1995). Recently, primary endothelial cells (ECs)
have been obtained from humans to uncover potential defects
that may promote various diabetic complications (Onat et al.,
2011). Current limitations that preclude widespread use of
human cell explants for diabetes research include the lack of
donor availability, limited lifespan of primary cells in in vitro cul-
tures, and the limited number of accessible and relevant cell
types for study.
iPSCs Represent a New Model for Studying Human
Diabetes
Induced pluripotent stem cells (iPSCs), generated by transcrip-
tion factor-dependent nuclear reprogramming of differentiated
somatic cells, are pluripotent stem cell lines that can be propa-
gated indefinitely in culture andmaintain the potential to differen-
tiate into any cell type in the body. As iPSCs retain the same
genetic makeup as the somatic cell targeted for reprogramming,
these cells hold tremendous promise for uncovering novel
genetic and biochemical factors that underlie diseases with
complex and poorly understood genetic influences, such as dia-
betes. In addition, human iPSCs (hiPSCs) may one day provide a
source of patient-specific replacement cells for b cells lost to dia-
betes, although realizing this possibility will also require effective
strategies to block the underlying autoimmunity (in T1D) or insu-
lin resistance (in T2D).
Accessible source 
of somatic cells
for reprogramming
Retroviruses
Lentiviruses
Transposons
Adenoviruses
Sendai viruses
Protein
Modified RNA
miRNA
Methods
of
reprogramming
Plasmid
Adipocytes
Dermal 
fibroblasts
Keratinocytes
Peripheral 
blood cells
hiPSC
Figure 2. Schematic of Derivation of hiPSCs
from Patient Somatic Cells
Types of human somatic cells, which are relatively
more accessible for reprogramming, include ker-
atinocytes, dermal fibroblasts, adipocytes, and
peripheral blood cells. Current reprogramming
methods include the use of retroviruses, lentivi-
ruses, plasmids, adenoviruses, Sendai viruses,
transposons, protein, modified RNA, and miRNA.
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Tremendous progress has been made in generating iPSCs.
Remarkably, delivery of genes encoding only three or four tran-
scriptions factors, including Oct3/4, Sox2, Klf4, c-Myc, Lin28,
and/or Nanog, or even a single microRNA (miRNA) cluster
(miR302/367), is sufficient to reprogrammouse and human fibro-
blasts, as well as other adult somatic cells, into pluripotent cells
(Takahashi and Yamanaka, 2006; Yu et al., 2007). These reprog-
rammed cells appear to be functionally equivalent to embryonic
stem cells (ESCs), although a minority of iPSC lines may have
distinct immunological properties (Zhao et al., 2011). Currently,
the greatest success in reprogramming is observed with the de-
livery of complementary DNAs (cDNAs) contained within retro-
viral or lentiviral vectors into somatic cells. In some cases, these
viral vectors have been modified to include flanking loxP ele-
ments, enabling transgene excision via transient delivery of Cre
recombinase (Chang et al., 2009), and limiting the impact of inte-
grational mutagenesis. An important goal for the long-term appli-
cation of iPSCs in research and therapy is the ability to produce
these cells without genotoxic events. Advances toward this goal
have been made through the demonstration that target cells canCell Metabolism 18, Dbe reprogrammed by transient transfec-
tion, nonintegrating adenoviral or Sendai
virus vectors, transposons, purified pro-
teins, modified RNAs, and miRNAs (see
Gonza´lez et al., 2011 for references)
(Figure 2); however, as of yet, the low
efficiency and high cost of many noninte-
grating methods have made their use in
iPSC generation infrequent (Bellin et al.,
2012). Although hiPSCs were first derived
from skin fibroblasts, a cell type that is still
commonly used, iPSCs also can be
derived from keratinocytes, melanocytes,
neural stem cells, mature B cells, renal
tubular cells, adipose stem cells, liver
and stomach cells, blood cells, as well
as pancreatic b cells (see Gonza´lez
et al., 2011; Robinton and Daley, 2012
for references) (Figure 2). Interestingly,
some studies suggest that the cell type
chosen for reprogramming may influence
subsequent iPSC differentiation poten-
tial. Particularly at early passages, blood
cell-derived iPSCs seem predisposed
for differentiation along the hematopoiet-
ic lineage (Polo et al., 2010), while b cell-
derived iPSCs show a predilection for
producting b-like cells (Bar-Nur et al.,2011). Yet, this apparent epigenetic memory appears to be lost
during extended in vitro passage (Polo et al., 2010) and has
not been observed for all reprogrammed cell types (Tan et al.,
2011).
Production and Uses of hiPSCs from Diabetic Patients
The generation of hiPSCs from humans with defined genetic
susceptibilities and well-documented medical histories presents
exciting new opportunities for understanding the complex
processes that underlie disease initiation and pathology. A great
diversity of human disorders have now been modeled using
iPSCs, including amyotrophic lateral sclerosis (ALS), spinal
muscular atrophy (SMA), familial dysautonomia (FD)/Riley-Day
syndrome, Rett syndrome, schizophrenia, Parkinson’s disease,
Hutchinson-Gilford progeria syndrome (HGPS), dyskeratosis
congenita, Fanconi anemia, LEOPARD syndrome, long QT syn-
drome, Timothy syndrome, alpha-1 antitrypsin deficiency, famil-
ial hypercholesterolemia, and glycogen storage disease type 1A
(Bellin et al., 2012; Robinton and Daley, 2012).
hiPSCs have also been generated from patients with diabetes
(Hua et al., 2013; Kudva et al., 2012; Maehr et al., 2009; Ohmine
et al., 2012; Park et al., 2008; Teo et al., 2013; Thatava et al.,ecember 3, 2013 ª2013 Elsevier Inc. 779
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does not represent the broad spectrum of phenotypes and geno-
types seen in the clinic. Successful generation of diabetic iPSCs
(DiPSCs) obviates one widely held concern regarding the use of
this technology for generating patient-specific cells and studying
diabetes pathogenesis: that underlying genetic abnormalities or
effects of systemic dysregulation of glucose homeostasis in dia-
betic patients might preclude effective reprogramming of their
cells to generate fully competent iPSCs. Indeed, while the re-
programming efficiency of cells from diabetic patients may not
be identical to that of healthy individuals, studies in several
labs clearly establish the feasibility of deriving hiPSCs from these
individuals. Nonetheless, there remains the real concern that the
process of reprogramming, which fundamentally alters the
global epigenetic profile of the reprogrammed cells (Polo et al.,
2010), may erase some key disease-contributing changes in
gene regulation and expression. Loss of such disease-specific
alterations, which may accumulate over many years in vivo,
could complicate efforts to accurately model diabetes patho-
genesis ex vivo using the reprogrammed cells.
DiPSCs have also been considered as a new and arguably
inexhaustible source of replacement cells for transplantation
approaches to restore b cell mass and reverse insulin depen-
dency in diabetes. One advantage of this approach is the poten-
tial to utilize autologous cells (derived from the same patient into
whom they are ultimately reimplanted) in certain situations. How-
ever, if b cell dysfunction arises in whole or in part from cell
intrinsic alterations, then correction of the disease-causing
mutations will be necessary prior to differentiation and reintro-
duction into patients of iPSC-derived b cells. In these cases, allo-
geneic (non-self) cellsmay have some advantages, particularly in
settings where the full spectrum of disease-contributing muta-
tions are unknown and probably numerous (e.g., T2D); however,
the use of allogeneic cells raises another challenge in that immu-
nological tolerance to the transplanted cells must be achieved,
traditionally through the use of immunosuppressive agents
and/or encapsulation devices, which have their own respective
limitations. Establishing immune tolerance will be particularly
critical for using iPSC-derived cells to replace b cells lost to
T1D, as the disease-instigating autoimmunity that remains in
these patients will likely mediate prompt rejection of trans-
planted autologous cells. Thus, for T1D patients, transplanta-
tion-based approaches utilizing iPSC cell products may require
replacement of both the diseased hematoimmune system
(through production of engraftable hematopoietic stem cells
[HSCs] from iPSCs) and the generation of glucose-responsive
mature b cells (discussed further below).
Given the significant (though certainly not insurmountable)
hurdles facing transplantation-based applications of iPSCs for
the treatment of diabetes, it may be argued that the greatest
near-term utility of these cells will be in their use as screening
tools for identifying new genes and pathways that contribute to
diabetes pathogenesis in humans and novel drugs that target
these pathways. In this regard, patient-specific hiPSCs carrying
mutations previously implicated through GWASs in diabetes
pathogenesis (seeMcCarthy, 2010 for review), may be corrected
(e.g., using sequence-specific zinc finger nuclease [ZFN], tran-
scription activator-like effector nuclease [TALEN], or clustered
regularly interspaced short palindromic repeat [CRISPR] tech-780 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.nology) by introduction of wild-type sequence at the locus in
question in order to evaluate the subsequent impact on cellular
activities. Conversely, disease-associated polymorphisms can
be introduced into the genomes of iPSCs from healthy donors
(Ding et al., 2013a; 2013b). These approaches provide a much-
needed functional test for the involvement of candidate diabetes
loci in the disease (Merkle and Eggan, 2013), and an important
alternative to mouse models, which can produce results that
are not perfectly translatable to the human system (Odom
et al., 2007; Tiscornia et al., 2011). However, such approaches
will depend on the production of disease-relevant differentiated
target cells in vitro, an ongoing challenge discussed further
below.
In the long term, in vitro studies using large panels of hiPSC-
derived target cells may provide an early-stage assessment of
the toxicity and efficacy of new candidate pharmaceuticals
and allow correlation with human genetic diversity to specifically
inform the design of subsequent clinical trials and ensure testing
on the most relevant human populations. Indeed, published
studies using iPSCs from SMA and FD patients have employed
cell-level readouts (e.g., nullification of messenger RNA
[mRNA] splicing errors) to identify compounds that reverse
disease-associated phenotypes (Ebert et al., 2009; Lee et al.,
2009). Similarly, a recent study testing the impact of small mole-
cules on patient-derived motor neurons differentiated in vitro
from ALS-hiPSCs actually predicted the failure of two com-
pounds that indeed proved ineffective in recent ALS clinical trials
(Yang et al., 2013).
In addition to neurological diseases, hiPSCs from patients with
cardiovascular disease have also been used for drug screening.
Cardiomyocytes from type 1 long QT syndrome-hiPSCs could
be treated with b-adrenergic receptor blockers (Moretti et al.,
2010), and iPSC-derived cardiomyocytes have also been tested
for compounds that might exacerbate disease (Kannankeril
et al., 2010). Similar analysis of cardiomyocytes derived from
type 2 long QT syndrome-hiPSCs have identified classes of
molecules that either aggravate or ameliorate disease pheno-
type (Itzhaki et al., 2011).
Thus, cells derived from patient-specific hiPSCs have identi-
fied drugs that are beneficial, as well as those that may be
ineffective or even detrimental, providing a novel means for pre-
dicting drug efficacy and toxicity against particular cell types in
a disease-specific manner. The use of similar approaches with
DiPSCs may discover new drugs for intervention in diabetes
and its complications.
Human-Induced Pluripotent Stem Cells as a Tool to
Model Diabetes In Vitro
Conventional models for studying diabetes frequently involved
the use of inbred rodents. Since humans are genetically diverse,
this could partly account for some clinical trial failures when
translating rodent findings to humans. Indeed, use of human
cells where available is probably themost fittingmodel for study-
ing human diseases. Therefore, DiPSCs serve as a valuable
resource for studying diabetes mechanisms. Cells derived
from DiPSCs can be used to understand the developmental
events that have gone awry during pancreatic organogenesis,
development of diabetic complications, or insulin resistance.
As discussed above, since diabetes is a complex disease
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modeling diabetes using hiPSCs can be most easily achieved
in monogenic forms of diabetes followed by efforts aimed at
understanding T1D and T2D. Among the monogenic forms of
diabetes, hiPSCs have only been reported for MODY and mito-
chondrial diabetes (Fujikura et al., 2012; Hua et al., 2013; Teo
et al., 2013). hiPSCs from T1D patients (Kudva et al., 2012;
Maehr et al., 2009; Park et al., 2008; Thatava et al., 2013) and
T2D patients (Kudva et al., 2012; Ohmine et al., 2012) have
also been generated.
Differentiation into diabetes-relevant cells types (neural,
retinal, and dermal cells, cardiomyocytes, endothelial cells, kid-
ney cells, skeletal myocytes, adipocytes, and hepatocytes) is
essential to fully harness the potential of DiPSCs for understand-
ing the pathogenesis of the various types of diabetes and their
complications. hiPSCs derived from MODY patients and infants
with neonatal diabetes can be used to understand the impor-
tance of causal genes in human pancreas development as well
as islet and b cell function. hiPSCs derived from patients with
mitochondrial diabetes can be differentiated into b cells to un-
derstand the mitochondrial defect that leads to diabetes. Simi-
larly, hiPSCs derived from patients with monogenic defects in
the insulin gene can be differentiated into b cells to understand
the impact of the specific mutation. hiPSCs from patients with
insulin receptor defects and monogenic forms of insulin resis-
tance can be differentiated into b cells, myocytes, adipocytes,
or hepatocytes to understand the pathogenesis of insulin resis-
tance, whereas hiPSCs from patients suffering from monogenic
forms of obesity can be differentiated into adipocytes to study
obesity and the initiation of insulin resistance. T1D-hiPSCs can
be used to model the immune attack on b cells or islet progeni-
tors in vitro, while T2D-hiPSCs can be used to study mecha-
nisms underlying insulin resistance. Efficient and reproducible
differentiation protocols are urgently required in order to carry
out the aforementioned in vitro disease modeling approaches.
To date, most protocols have been developed by mimicking
developmental events: modifying the dose and timing of activa-
tors, repressors, and growth factors (Murry and Keller, 2008).
Many of these protocols have been initially designed for human
embryonic stem cells (hESCs) and subsequently applied to
hiPSCs, collectively known as human pluripotent stem cells
(hPSCs). These will be highlighted and further elaborated upon
in the following sections focusing on the differentiation of
DiPSCs into pancreatic cells as well as cell types involved in dia-
betic complications and insulin resistance.
Differentiating hiPSCs from Diabetic Patients into
Pancreatic Cells to Study theDisease Phenotype In Vitro
There have been numerous attempts to derive pancreatic cells
from hPSCs to treat diabetes and, as a corollary, to study human
pancreas development in vitro (see Table S3 for references).
These efforts have frequently been based on a stepwise differen-
tiation of hPSCs toward definitive endoderm, primitive gut tube,
foregut, ventral and dorsal pancreatic endoderm, pancreatic
progenitors, and ultimately to insulin-producing b-like cells.
Indeed, the ability of islet transplantation via the Edmonton pro-
tocol to render diabetic patients insulin independent (Shapiro,
2011) suggests a potential for hPSC-derived pancreatic b-like
cells to treat T1D (see Table S3 for reviews).ViaCyte was among the first to demonstrate the ability of
hESC-derived pancreatic progenitors to mature in vivo, after
5months, into glucose-responsive insulin-secreting b-like cells
(Kroon et al., 2008). Further, they recently succeeded in scaling
their protocol toward a typical manufacturing process. This
manufacturing scale could eventually make the derivation of
these cells feasible for clinical use (Schulz et al., 2012). Alterna-
tively, in order to produce large quantities of differentiated b-like
cells, endodermal progenitor cells can be established from
hPSCs (Cheng et al., 2012). Nonetheless, all protocols estab-
lished to date are only able to produce immature b-like cells at
best. That said, although the generation of mature and fully func-
tional hPSC-derived b cells in vitro is far from reality, the signifi-
cant progress made by these approaches can be effectively
translated to DiPSCs in order to better understand diabetes
disease mechanisms, which are still poorly understood. In addi-
tion to b cells, hPSC-derived a cells are also significant in the
context of diabetes, given their importance in regulating glucose
homeostasis (Rezania et al., 2011) as well as the emerging evi-
dence that a cells can transdifferentiate into b cells (see Table
S3 for references). Notwithstanding, both cell types can be
derived to investigate how their direct interaction regulates insu-
lin versus glucagon secretion. In the following section, we will
briefly discuss the relevance of DiPSC-derived pancreatic cells
for each type of diabetes.
Monogenic Forms of Diabetes
HNF4A (MODY1) mutations affect the secretory function of b
(Byrne et al., 1995), a, and pancreatic polypeptide (PP) cells
(Ilag et al., 2000), leading to low basal and stimulated insulin
secretion as well as severe diabetes, which often requires insulin
therapy (Fajans et al., 2001). The availability of MODY1-hiPSC-
derived b cells provides an opportunity to specifically investigate
the role of HNF4A in human pancreas development and b cell
function. GCK (MODY2 and neonatal diabetes) controls the
rate of glucose entry into the glycolytic pathway (glucose phos-
phorylation) and the rate of its subsequent metabolism (Mat-
schinsky et al., 1998). The majority of GCK mutations render b
cells insensitive to normal extracellular glucose levels (glucose-
sensing defect, glucose blindness, decreased glycolytic flux),
causing modest hyperglycemia, an increase in blood glucose
threshold that triggers insulin secretion (insulin secretion impair-
ment) (Velho et al., 1992), and glucose intolerance, leading to a
mild form of diabetes. MODY2-hiPSC-derived pancreatic b cells
would be important in unraveling the impact of specific GCK
mutations on pancreatic b cell function (Hua et al., 2013).
MODY3 (HNF1A) has a b cell phenotype extremely similar to
that of MODY1, likely because HNF4A regulates HNF1A gene
expression (Ferrer, 2002). The major function of HNF1A is prob-
ably to ensure that the machinery required by b cells to respond
to glucose and other stimuli is in place. b cell dysfunction in
MODY3 patients is hypothesized to be caused by dominant-
negative effects (Yamagata et al., 1998) or loss-of-function
mechanisms, such as reduced DNA binding, impaired transcrip-
tional activation, and defects in subcellular localization (Bjør-
khaug et al., 2003). This is still to be determined for each specific
mutation. Pdx1 (MODY4 and neonatal diabetes) is an extremely
important gene required for embryonic development of pancre-
atic islets, without which near-complete pancreatic agenesis
occurs (Jonsson et al., 1994). The impact of various PDX1Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 781
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be determined. HNF1B (MODY5 and neonatal diabetes) is a
member of the complex transcriptional regulatory network that
includes HNF1A and HNF4A. HNF1B and HNF1A proteins share
a high degree of sequence homology (Mendel et al., 1991),
accounting for common pathophysiological mechanisms be-
tween b cells of MODY5 and MODY3. Hnf1b/ mice rescued
by tetraploid complementation do not form the ventral bud and
exhibit pancreatic agenesis by embryonic day 13.5 (E13.5) (Hau-
maitre et al., 2005). Interestingly, some MODY5 patients exhibit
dorsal pancreatic agenesis (Haldorsen et al., 2008). Mechanisms
underlying HNF1B mutation and diabetes remain to be thor-
oughly explored.
Neurogenic differentiation 1 (NEUROD1)/beta cell E box trans-
activator 2 (BETA2) (MODY6 and neonatal diabetes) is involved
in regulating pancreatic endocrine development. NeuroD1/
mice exhibit abnormal pancreatic islet morphogenesis (reduced
number of endocrine cells and no formation of islets) and
decreased expression of the insulin gene (Naya et al., 1997).
The impact of NEUROD1 mutations on human pancreatic func-
tion is to be further studied. Little is known about the role of
Sp1/Kru¨ppel-like factor 11 (KLF11) (MODY7) in pancreas devel-
opment and b cell function, except that it regulates PDX1 gene
expression (Fernandez-Zapico et al., 2009). Klf11/ mice are
surprisingly normal (Song et al., 2005). Pancreatic cells differen-
tiated fromMODY7-hiPSCs will certainly shed light on themech-
anism bywhichKLF11mutation causes diabetes. Carboxyl ester
lipase (CEL) (MODY8) or bile salt-dependent lipase (BSDL) is a
major component of pancreatic juice and is responsible for
duodenal hydrolysis of cholesterol esters. Cel/ mice exhibit
normal glucose metabolism and do not seem to exhibit
MODY8 phenotype (Vesterhus et al., 2010). MODY8 patients
exhibit pancreatic exocrine disease before diabetes, and the
exocrine disturbance is linked to an abnormal structure of the
pancreas. How mutations in the variable number of tandem re-
peats (VNTR) of CEL exon 11 result in diabetes is unclear as of
yet (Raeder et al., 2006). Thus, differentiation of MODY8-hiPSCs
into pancreatic exocrine tissue could shed light on the disease
mechanisms. Although there has been relatively less interest in
differentiating hPSCs into pancreatic exocrine tissue, an
embryoid body (EB) differentiation protocol has been recently re-
ported (Shirasawa et al., 2011). Pax4 (MODY9) regulates gene
expression patterns in pancreatic endocrine progenitors.
Pax4/ mice exhibit a loss of b (Collombat et al., 2005) and
d cells (Prado et al., 2004). MODY9-hiPSCs serve to explore
the impact of mutations affecting the function of PAX4 in pancre-
atic b cells. Insulin (INS) (MODY10 and neonatal diabetes) is a
hormone produced by pancreatic b cells to regulate carbohy-
drate and fat metabolism, thereby maintaining euglycemia.
Loss of insulin is the main cause of diabetes. MODY10-hiPSCs
can be used to study insulin structural defects caused by muta-
tions in the INS gene (Molven et al., 2008). Similarly, hiPSCs
derived from infants with neonatal diabetes can be used to study
how mutations result in preproinsulin or proinsulin structural
abnormalities. B lymphocyte kinase (BLK) (MODY11) is a nonre-
ceptor tyrosine kinase of the src family of proto-oncogenes
(Dymecki et al., 1990) expressed in b cells. It is yet unknown
why BLK mutations result in diabetes. No metabolic phenotype
was reported in Blk/ mice (Texido et al., 2000), although BLK782 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.is involved in upregulating Pdx1 and Nkx6.1 gene expression
to enhance insulin synthesis and secretion (Borowiec et al.,
2009).
KCNJ11 and ABCC8 (neonatal diabetes) encode for ATP-
sensitive inward rectifier potassium channel 11 (Kir6.2) and
ATP-binding cassette transporter subfamily C member 8
(SUR1), respectively, components of the b cell KATP channel. In
infants with KCNJ11 or ABCC8 mutation, the KATP channels
are dysfunctional and cannot close properly. The intracellular
ATP is unable to close the KATP channel due to reduced ATP
sensitivity. The resulting increased KATP current hyperpolarizes
the b cell membrane, thereby suppressing Ca2+ entry. As a
result, glucose-stimulated insulin secretion (GSIS) cannot occur
(Hattersley and Ashcroft, 2005). DiPSCs derived from these in-
fants could be differentiated into b cells to study their electro-
physiology and to determine how each mutation affects the
conformational change of the KATP channel. The MT-TL1 gene
(mitochondrial diabetes) transfers leucine during polypeptide
synthesis. It is involved in synthesizing proteins that participate
in oxidative phosphorylation reactions and ATP production in
themitochondria. The A3243Gmutation leads to impaired insulin
secretion in the presence of normal insulin sensitivity, as cells are
unable to produce sufficient ATP (Maassen et al., 2005). It is still
unclear how the mutation specifically impairs pancreatic b cells
and causes age-dependent loss of b cell function.
Type 1 Diabetes and Type 2 Diabetes
T1D-hiPSCs can be used for differentiation into pancreatic b
cells and various immune cells to determine the specific mecha-
nisms of autoimmune attack. The severity of attack by each type
of immune cell, the cytotoxic cytokines secreted by the cells, and
whether there is synergism between different types of immune
cells acting on the pancreatic b cells can be explored. T2D-
hiPSC-derived pancreatic b cells would be useful for modeling
mechanisms of secretory dysfunction and the effects of insulin
resistance. Potential areas of study include stimulus-secretion
coupling, mitochondrial function, growth factor (e.g., insulin,
IGF-I) signaling, and the testing of inducers of T2D pancreatic
b cell failure.
Concluding Remarks
Modeling monogenic forms of diabetes with the use of DiPSC-
derived pancreatic b cells can potentially inform us about human
pancreas development. Correction of the mutations with the use
of ZFNs, TALENs, or CRISPRs will provide ideal isogenic con-
trols for such studies. Similarly, T1D- and T2D-hiPSC-derived
pancreatic b cells will provide unprecedented access into mech-
anisms of b cell failure and diabetes disease progression. Even-
tually, these hiPSC-derived b cells can also be subjected to
treatment with pharmaceutical compounds to identify drugs
that can effectively stimulate (1) GSIS in these defective b cells
and (2) b cell proliferation.
Differentiation of DiPSCs into Nonpancreatic Lineages
Involved in Complications of Diabetes and Insulin
Resistance
Prolonged hyperglycemia affects many other cell types in the
body besides pancreatic b cells. In most instances, these human
cells are inaccessible for investigation. Therefore, hiPSCs
derived from patients with diabetes due to diverse etiologies
can be used to study the disease progression in cell types
Figure 3. Differentiation of Diabetic hiPSCs
into Various Cell Types for In Vitro Disease
Modeling
Each type and/or source of diabetic hiPSCs can
be differentiated into relevant cell types of interest
for investigating disease mechanisms. Cell types
of interest include pancreatic cells, cells involved
in diabetic complications, and cells involved in
insulin resistance.
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omyocytes, endothelial cells, and kidney cells, including mesan-
gial cells and podocytes) as well as cell types involved in insulin
resistance (skeletal myocytes, adipocytes, and hepatocytes)
(Figure 3).
Neural Cells for Diabetic Neuropathy and Ischemic
Stroke
Diabetic neuropathy is a pathophysiological condition that
generally affects all peripheral nerves and the autonomic ner-
vous system. This condition is partly attributed to microvascular
complications since reduced blood flow results in neuronal
ischemia. Mechanisms underlying diabetic neuropathy are
poorly understood. Coculture of endothelial cells (discussed
below) with sensory neurons, motor neurons, and interneurons
derived from DiPSCs can potentially be used to study the impact
of hyperglycemia on blood vessel cells and neurons in conditions
of diabetic neuropathy.
Ischemic stroke is a severe complication in patients with dia-
betes; its occurrence in the cerebral cortex, cerebellum, andCell Metabolism 18, Dbrain stem can result in varied symptoms
due to the specialized functions of the
central nervous system. The area of the
brain that is affected probably loses its
function. Thrombosis (blood clot obstruc-
tion) or arterial embolism results in blood
flow blockade, thereby affecting brain
function. Thrombosis occurs gradually,
and thus the onset of ischemic stroke is
slow. However, the blockade of an artery
by a moving clot (embolus) is sudden, re-
sulting in a severe and immediate onset
of ischemic stroke. Occlusion of blood
vessels in the brain depletes oxygen
and glucose that is necessary for aerobic
metabolism and cell survival. Neuronal
death subsequently occurs, and neural
circuits are disrupted.
Neural cells in the brain include
neurons, astrocytes, and oligodendro-
cytes. The majority of the neurons in the
brain are either glutamatergic (release
glutamate; excitatory in general) or
GABAergic (release g-aminobutyric acid
[GABA]; inhibitory in general). Other types
include cholinergic (release acetylcho-
line), dopaminergic (release dopamine),
and serotonergic (release serotonin).
Neural differentiation from hPSCs (Erceg
et al., 2009) has advanced considerablydue to its relative ease as compared to deriving other cell types
of the body. hPSCs can be differentiated into neural precursors
readily (see Table S3 for references) and even more specifically
to neural cells, such as motor neurons (Boulting et al., 2011),
dopaminergic neurons (Swistowski et al., 2010), and glutamater-
gic neurons (Zeng et al., 2010). hPSC-derived neural precursors
have been reported to engraft in the rodent forebrain and pro-
mote recovery after a stroke (Oki et al., 2012). Although neural
differentiation is relatively advanced, the differentiation of hPSCs
into more specialized neuronal subtypes is still needed in order
to study mechanisms underlying diabetic neuropathy in vitro.
Retinal Cells for Diabetic Retinopathy
Retinopathy is a leading cause of blindness and occurs when
blood vessels of the retina are damaged, leading to vascular
leakage in patients with diabetes. Vascular leakage can lead to
macular edema, retina ischemia, and neovascularization fol-
lowed by vitreous hemorrhage and retinal detachment. DiPSCs
can be differentiated into retinal cells and endothelial cells (dis-
cussed below), and the interactions between these two cellecember 3, 2013 ª2013 Elsevier Inc. 783
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understanding mechanisms underlying diabetic retinopathy,
hiPSCs can also potentially be a source of cells for stem cell ther-
apy in retinal diseases (Rowland et al., 2012).
Significant progress has been made in the differentiation of
hPSCs into progenitor cells with a retinal cell fate (see Table
S3 for references), and hPSC-derived retinal cells have been
reported to integrate into rodent retina, demonstrating surviv-
ability and compatibility (Hambright et al., 2012). Swine-iPSC-
derived photoreceptors can integrate into the subretinal space
of pigs (Zhou et al., 2011), thereby establishing a larger animal
model for cell transplantation. One can now distinguish between
the various types of retinal cells derived from hPSCs, due to their
unique transcriptional profile (Siegert et al., 2012).
Dermal Cells for Diabetic Foot Ulcer
Diabetic foot ulcer occurs due to diabetic neuropathy as well as
macrovascular and/or microvascular complications. Peripheral
neuropathy (loss of feeling in extremities) and muscle atrophy
initially occurs, leading to foot ulcers. The wound-healing pro-
cess is impaired, thereby leading to gangrene and amputation.
DiPSCs can be differentiated into neural cells andmyocytes (dis-
cussed in other sections) to investigate how neuropathy affects
skeletal muscle integrity and function. Specific to dermal cells,
DiPSCs can be differentiated into keratinocytes and fibroblasts
to study the relationship between extracellular matrix (ECM)
replacement and prolonged inflammatory process in diabetic
wounds.
Dermal cells derived from DiPSCs are valuable for studying
ultrastructural components such as endoplasmic reticulum,
changes in secreted ECM proteins, and tissue-remodeling
enzymes. They also have the potential to be used in skin grafts
(Pellegrini and De Luca, 2010). hESCs have been reported to
differentiate into keratinocyte precursors and keratinocytes
and into structures resembling the skin (see Table S3 for refer-
ences). Once keratinocytes and fibroblasts are obtained, a
three-dimensional human skin reconstruction (Li et al., 2011)
could potentially be developed to model diabetic foot ulcer.
Cardiomyocytes for Diabetic Cardiomyopathy
Cardiovascular complications in patients with diabetes include
cardiomyopathy, which commonly occurs in the presence of
hypertension and atherosclerotic CAD. Cardiomyopathy is initi-
ated with some form of left ventricular dysfunction followed by
cardiomyocyte hypertrophy and an eventual long QT interval
indicative of fibrosis. In the face of constant hyperglycemia, car-
diomyocytes develop metabolic abnormalities, denervation due
to neuropathy, and dysregulated Ca2+, Na+, and K+ ion homeo-
stasis. Usually, the heart obtains up to 70% of the total required
ATP via oxidation of fatty acids. However, this is increased to
100% (Oliver andOpie, 1994) due to a decrease in glucosemeta-
bolism as the cardiomyocytes downregulate insulin-dependent
glucose transporter GLUT4 to protect themselves from hyper-
glycemia. The increased lipid uptake translates to triacylglycer-
ide (TAG) synthesis, and these metabolic changes ultimately
lead to diabetic cardiomyopathy.
Cardiomyocytes can now be derived from hPSCs with relative
ease (see Table S3 for reviews). Thus, DiPSCs can be differen-
tiated into cardiomyocytes (see Table S3 for references) to
study the impact of hyperglycemia on cardiomyocytes them-
selves. This approach is useful since it is virtually impossible784 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.to access human cardiomyocytes to study disease mecha-
nism(s).
Endothelial Cells for Various Diabetic Complications
Persistent extracellular hyperglycemia results in ECs lining the
blood vessels to be exposed to intracellular hyperglycemia, as
they are unable to regulate glucose uptake in contrast to myo-
cytes or hepatocytes. This leads to endothelial dysfunction and
blood vessel damage (angiopathy) (Brownlee, 2005). Complica-
tions in patients with diabetes arising from impaired ECs can be
categorized intomacrovascular (arteries) or microvascular (small
blood vessels: arterioles and capillaries) complications. Macro-
vascular complications implicate ischemic stroke, diabetic foot
ulcer, and atherosclerotic CAD, whereas microvascular compli-
cations lead to diabetic neuropathy, retinopathy, cardiomyopa-
thy, and nephropathy.
In macroangiopathy, endothelial dysfunction affects blood
flow and possibly capillary occlusion. Thus, all cells that depend
on blood vessels for glucose and oxygen potentially suffer from
ischemia and eventually die. CAD is a severe cardiovascular dis-
ease that occurs as a result of the narrowing of the lumen of
arteries due to plaque accumulation. The restriction of blood
flow to the myocardium results in myocardial ischemia and ulti-
mately myocardial infarction (tissue death; heart attack). Hyper-
glycemia also results in basement membrane thickening and
changes in blood vessel permeability. This condition of micro-
angiopathy results in leakage of fluid and protein, edema, and
decreased blood flow to tissues and cells. The impact of
hyperglycemia on EC function is variable in the various diabetic
conditions. Thus, it would be fruitful to differentiate DiPSCs into
endothelial cells and cell types that are location and condition-
specific to determine the specific dysfunctions in ECs. hPSCs
can be differentiated into vascular endothelial cells. See Table
S3 for reviews and references to protocols involving the differen-
tiation of ECs from hPSCs.
Kidney Cells for Diabetic Nephropathy
Diabetic nephropathy occurs when blood vessels in the kidney
glomeruli suffer from microangiopathy. The glomeruli thicken
and leak serum albumin in the urine (microalbuminuria), and
this defect progresses to macroalbuminuria and proteinuria.
Often, these patients have increased serum creatinine and
decreased estimated glomerular filtration rates (eGFR). Un-
treated diabetic nephropathy may progress toward end-stage
renal disease (ESRD), whereby the kidney fails to function. The
mechanisms underlying diabetic nephropathy have been difficult
to study in humans due to inaccessibility of the renal corpuscle
(which filters the blood) during disease progression. The renal
corpuscle is made up of the glomerulus and the Bowman’s
capsule. Fluid from the blood passes through the endothelial
cells of the glomerulus, the mesangial cells (pericytes) around
the blood vessels, and the podocytes lining the Bowman’s
capsule. Thus, the reconstitution of these components in vitro
with the use of DiPSC-derived cells may provide insights into
the mechanisms underlying disease progression.
Unfortunately, there has been little success thus far in deriving
kidney cells from hPSCs. Three reports suggest the feasibility of
deriving renal progenitors from hESCs (Batchelder et al., 2009;
Lin et al., 2010; Narayanan et al., 2013). To understand the inter-
actions between endothelial cells, mesangial cells, and podo-
cytes, these renal progenitors need to be derived in vitro. While
Cell Metabolism
Reviewmesangial cells are known to communicate with the endothelial
cells (Kida and Duffield, 2011), additional efforts are required to
derive these cell types in order to model diabetic nephropathy.
Skeletal Myocytes for Diabetic Foot Ulcer and Insulin
Resistance
Skeletal myocytes can potentially be derived from DiPSCs to
study the progression of diabetic foot ulcer as well as mecha-
nisms underlying insulin resistance. How diabetic neuropathy
and damaged innervation result in muscle weakness and atro-
phy is not well understood in diabetic foot ulcer. In patients
with insulin resistance, skeletal myocytes do not respond appro-
priately to insulin to absorb glucose and convert it to glycogen.
Less glucose is absorbed from the blood, and less glycogen is
produced.
Skeletal muscle contains a resident stem cell population
(satellite cells) that supports regenerative myogenesis, and
several groups have attempted to derive these cells as well as
differentiated skeletal myoblasts from hPSCs. Skeletal myocytes
derived from hPSCs may be useful to study the initiation and
development of insulin resistance in vitro. However, the estab-
lishment of robust protocols for deriving such cells from hPSCs
has proved challenging. One report described skeletal myocyte
derivation from human embryonic germ cells (Kim et al., 2005).
Most published protocols to date typically rely on enforced
expression of myogenic transcription factors or inclusion of an
intermediate step inwhich hPSCs are first differentiated intomul-
tipotent mesenchymal stromal cells (MSCs), which must be
further cultured to allow differentiation into myocytes (see Table
S3 for additional references).
Adipocytes for Monogenic Diabetes and Insulin
Resistance
Various gene mutations affect adipocyte development and/or
function and result in syndromes of insulin resistance. Indeed, in-
sulin resistance in T2D also affects adipocytes. Thus, one new
exciting area of research is the differentiation of DiPSCs into
adipocytes to studymechanisms of development of insulin resis-
tance. Adipocytes normally respond to insulin by taking up
glucose and converting it into TAGs and by taking up excess
lipids for storage. In states of insulin resistance, dysfunctional
adipocytes exhibit reduced lipid uptake and increased hydroly-
sis to TAGs, increasing circulating free fatty acids (FFAs). The
inability to store excess lipids in fat leads to lipid accumulation
in myocytes and hepatocytes. Adipocyte growth and expansion
also results in inflammation. Cytokines are produced, leading to
the recruitment of macrophages. Macrophage accumulation
leads to further production of cytokines and, ultimately, the pro-
motion of inflammation in tissues, including the islets (insulitis).
These cumulative events may contribute to insulin resistance.
Several of these pathways could be investigated at early stages
of differentiation of DiPSCs into adipocytes. Primate ESCs,
similar to hPSCs, can be differentiated into adipocytes (see Ta-
ble S3 for references). Alternatively, hPSCs can be differentiated
into multipotent MSCs and, subsequently, to preadipocytes via
BMP4 (see Table S3 for references).
Hepatocytes for Monogenic Diabetes and Insulin
Resistance
HNF4A (MODY1) plays a critical role in liver development (Hay-
hurst et al., 2001) besides pancreatic development. MODY1
patients exhibit lower levels of serum protein, TAG concentra-tions (Shih et al., 2000), and esterified cholesterol (Pramfalk
et al., 2009). GCK (MODY2) is also expressed in hepatocytes
besides pancreatic b cells (Iynedjian et al., 1989). In fact, most
of the GCK in the body is found in hepatocytes. GCK has b cell
and hepatocyte-specific promoters that can produce different
GCK isoforms (Stoffel et al., 1992). Clearly, the role of GCK in
hepatocytes and b cells is different, as GCK in the liver generally
processes all available glucose, whereas it is a glucose sensor in
the pancreas.
Hepatocyte-like cells have been derived from hPSCs (see
Table S3 for references). MODY1-hiPSC-derived hepatocytes
can be used to investigate the importance of HNF4A in hepato-
cyte development and function. Given that GCK is largely
expressed in hepatocytes, the differentiation of MODY2-hiPSCs
into hepatocytes is a good model to study the effect of GCK
mutations on hepatocyte glucose metabolism. In addition, the
same GCK mutant protein can be compared in MODY2-hiPSC
differentiated pancreatic b cells versus hepatocytes. Mutant
GCK results in impaired insulin secretion and abnormal liver
glucose metabolism (Velho et al., 1996). It will be important to
understand the impact of mutant GCK on pancreatic b cell and
hepatocyte function, independent of their physiological cross-
talk. The differentiation of T2D-hiPSCs into hepatocytes would
allow the creation of a useful in vitro model to study insulin resis-
tance in hepatocytes, independent of whole body physiology.
Using hiPSC Derivatives to Investigate Metabolic
Signaling Pathways Relevant to Maintenance of
Pluripotency and Differentiation
Traditional metabolic signaling pathways, such as the insulin/
IGF-I signaling pathway, are emerging as important in iPSC
biology due to their diverse roles in growth, metabolism, and
relevance throughout the developmental stages of cellular differ-
entiation. The pathways regulated by insulin/IGF-I, and their
downstream proteins PI3K/Akt, and Raf/MEK/ERK (mitogen-
activated protein kinase, MAPK) signaling will be briefly dis-
cussed.
Insulin/IGF-I Signaling
Insulin and insulin-like growth factors (IGF-I and IGF-II) are ubiq-
uitous growth factors that modulate growth as well as glucose
and lipid metabolism. They bind to insulin receptor (IR) and/or
insulin-like growth factor 1 receptor (IGF1R), both receptor tyro-
sine kinases (RTKs), leading to autophosphorylation of the IR/
IGF1R. This initiates a chain of signaling events, including the
phosphorylation of insulin receptor substrate (IRS) proteins,
recruitment of adaptor molecules, and activation of (1) PI3K/
Akt/PKB or (2) Raf/MEK/ERK (MAPK) signaling pathways (Tani-
guchi et al., 2006) (discussed below).
Insulin/IGF-I signaling has been suggested to play important
roles in both the maintenance of hPSC pluripotency (Chen
et al., 2011) and cell metabolism in adult tissues (Rask-Madsen
and Kahn, 2012). IGF-I regulates hESC pluripotency (Wang
et al., 2007), whereas IGF-II promotes hESC proliferation, expan-
sion, and prevention of apoptosis (Bendall et al., 2007). In using
DiPSCs to study disease mechanisms, one can also investigate
the role of insulin/IGF-I signaling from the pluripotent state
of hiPSCs, during directed differentiation, and in specific cell
types involved in glucose and lipid metabolism. In this respect,
how the requirement for insulin/IGF-I signaling in maintainingCell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 785
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Reviewpluripotency (McLean et al., 2007) tapers and transits toward
early differentiation can provide new insights into energy usage.
Furthermore, in defined cell types such as myocytes and adipo-
cytes, one can investigate the switch in insulin/IGF-I signaling
pathway in the regulation of glucose uptake.
PI3K/Akt Signaling Pathway. Phosphatidylinositol 3-kinase
(PI3K), a lipid kinase, consists of a p85 regulatory subunit and
a p110 catalytic subunit. Activation of PI3K signaling pathway
results in phosphorylation of phosphatidylinositol (4,5) bisphos-
phate (PtdIns[4,5]P2), formation of Ptd(3,4,5)P3, and activation
and/or phosphorylation of serine/threonine kinase Akt/protein
kinase B (PKB). Akt then phosphorylates and inhibits glycogen
synthase kinase 3 (GSK-3) and induces glycogen synthesis.
Activated Akt also participates in cell survival, inhibition of proap-
optotic signals, cell proliferation, cell growth, and protein synthe-
sis (Cantley, 2002).
Insulin signaling via the PI3K signaling pathway can increase
epiblast cell number (Campbell et al., 2012), suggesting the
importance of this pathway in hPSC proliferation. In addition,
PI3K signaling is also important for the maintenance of pluripo-
tency of hPSCs, as its suppression by LY294002 and/or AKT1-
II is required for the transition from pluripotency to differentiation
(McLean et al., 2007). A decrease in PI3K/Akt signaling pathway
has been reported following hESC differentiation (Armstrong
et al., 2006). Given that PI3K/Akt signaling mediates stem cell
fate (Welham et al., 2007), the dynamics of PI3K/Akt signaling
can be studied upon differentiation of hiPSCs into diverse cell
types.
Raf/MEK/ERK MAPK Signaling Pathway. MAPKs are serine/
threonine protein kinases, and their signaling pathway involves
adaptor proteins, guanine nucleotide exchange factors, and
small guanosine triphostphate (GTP) binding proteins. These
then activate MAPK kinase kinase (MAPKKK)/Raf, which phos-
phorylates MAPK kinase (MAPKK)/MEK1/MEK2, which in turn
phosphorylates MAPK/ERK1/ERK2. This signaling cascade is
important for cell growth, cell proliferation, cell movement, cell
differentiation, and cell death (Keshet and Seger, 2010).
Insulin/IGF-I signaling pathway activation activates the MAPK
signaling pathway. FGF2, an important component required to
maintain pluripotency of hPSCs, activates FGFR2 and also stim-
ulates MAPK signaling (Eiselleova et al., 2009). FGF2 reinforces
the pluripotent state, self-renewal, and survival, and it has
been reported that a high basal level of MAPK signaling pathway
maintains pluripotency in hESCs, in contrast to mESCs (Li et al.,
2007). Also, upon hESC differentiation, there is a decrease in
MAPK signaling pathway (Armstrong et al., 2006). Since both
insulin/IGF-I and FGF2 independently activate MAPK signaling
in hPSCs, it would be interesting to determine their relative roles
in the maintenance of pluripotency. MAPK signaling also regu-
lates developmental cell fate specification (Craig et al., 2008)
and stem cell lineage commitment (Bine´truy et al., 2007). Given
that insulin/IGF-I and FGF2 are also known to play mitogenic
roles during differentiation of hiPSCs, this signaling network
can be actively studied during the differentiation of DiPSCs
into the various cell types.
Future Directions and the Road to Therapy
In conclusion, hiPSCs derived from patients with diabetes or
various types of metabolic syndromes can be effectively derived786 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.and used to study disease development and pathology in vitro. In
this regard, the study of monogenic diabetic or metabolic dis-
eases may be more straightforward in terms of carrying out
in vitro disease modeling with hiPSCs, compared to complex
diseases such as T1D and T2D, as the lengthy evolution and
ever-changing genetic-environmental interactions that occur in
T1D and T2D are potentially harder to decipher using cell-based
systems. Understanding the significance of MODY genes in the
differentiation and maturation of pancreatic islet cells may be
particularly illuminating for enhancing ex vivo strategies to
produce mature, functional b cells. Likewise, small-molecule
screening using DiPSC-derived cells may identify patient-spe-
cific susceptibilities to therapy and advance personalized
approaches to diabetes treatment. It must be cautioned, how-
ever, that considerable progress is still necessary to achieve
accurate specification of fully mature cells from differentiating
hiPSCs and to enable delivery of hiPSC-derived cells to appro-
priate target organs in vivo. Continued progress on these fronts
will be critical in uncovering new mechanisms underlying dia-
betes pathology and advancing treatment options for diabetes
patients.SUPPLEMENTAL INFORMATION
Supplemental Information includes three tables and can be found with this
article online at http://dx.doi.org/10.1016/j.cmet.2013.08.010.ACKNOWLEDGMENTS
The authors would like to thank Julia Li for assistance with the graphics and
apologize to all those whose work was not discussed and cited due to space
constraints. A.K.K.T. is supported by a Juvenile Diabetes Research Founda-
tion Postdoctoral Fellowship. R.N.K. is supported by National Institute of
Health grants RO1DK 67536 and RO1DK 055523, the Harvard StemCell Insti-
tute, a JDRF/Sanofi Strategic Alliance Grant, and a grant from the Astra
Zeneca. This work was also supported by a Diabetes Research Center grant
(NIH P30DK036836) to the Joslin Diabetes Center. The authors declare no
conflicts of interest.REFERENCES
Abbate, M., Cravedi, P., Iliev, I., Remuzzi, G., and Ruggenenti, P. (2011). Pre-
vention and treatment of diabetic retinopathy: evidence from clinical trials and
perspectives. Curr. Diabetes Rev. 7, 190–200.
Aguilar-Bryan, L., and Bryan, J. (2008). Neonatal diabetes mellitus. Endocr.
Rev. 29, 265–291.
Aleixandre de Artin˜ano, A., and Miguel Castro, M. (2009). Experimental rat
models to study the metabolic syndrome. Br. J. Nutr. 102, 1246–1253.
Alpers, C.E., and Hudkins, K.L. (2011). Mousemodels of diabetic nephropathy.
Curr. Opin. Nephrol. Hypertens. 20, 278–284.
Andersen, H. (2012). Motor dysfunction in diabetes. DiabetesMetab. Res. Rev.
28(Suppl 1 ), 89–92.
Antonetti, D.A., Klein, R., and Gardner, T.W. (2012). Diabetic retinopathy.
N. Engl. J. Med. 366, 1227–1239.
Armstrong, L., Hughes, O., Yung, S., Hyslop, L., Stewart, R., Wappler, I.,
Peters, H., Walter, T., Stojkovic, P., Evans, J., et al. (2006). The role of PI3K/
AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human
embryonic stem cell pluripotency and viability highlighted by transcriptional
profiling and functional analysis. Hum. Mol. Genet. 15, 1894–1913.
Baker, P.R., 2nd, and Steck, A.K. (2011). The past, present, and future of
genetic associations in type 1 diabetes. Curr. Diab. Rep. 11, 445–453.
Cell Metabolism
ReviewBar-Nur, O., Russ, H.A., Efrat, S., and Benvenisty, N. (2011). Epigenetic mem-
ory and preferential lineage-specific differentiation in induced pluripotent stem
cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17–23.
Barker, A., Langenberg, C., and Wareham, N.J. (2012). Genetic determinants
of glucose homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 26,
159–170.
Batchelder, C.A., Lee, C.C., Matsell, D.G., Yoder, M.C., and Tarantal, A.F.
(2009). Renal ontogeny in the rhesus monkey (Macaca mulatta) and directed
differentiation of human embryonic stem cells towards kidney precursors.
Differentiation 78, 45–56.
Bellin, M., Marchetto, M.C., Gage, F.H., and Mummery, C.L. (2012). Induced
pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13, 713–726.
Bendall, S.C., Stewart, M.H., Menendez, P., George, D., Vijayaragavan, K.,
Werbowetski-Ogilvie, T., Ramos-Mejia, V., Rouleau, A., Yang, J., Bosse´, M.,
et al. (2007). IGF and FGF cooperatively establish the regulatory stem cell
niche of pluripotent human cells in vitro. Nature 448, 1015–1021.
Bine´truy, B., Heasley, L., Bost, F., Caron, L., and Aouadi, M. (2007). Concise
review: regulation of embryonic stem cell lineage commitment by mitogen-
activated protein kinases. Stem Cells 25, 1090–1095.
Bingham, C., Bulman, M.P., Ellard, S., Allen, L.I., Lipkin, G.W., Hoff, W.G.,
Woolf, A.S., Rizzoni, G., Novelli, G., Nicholls, A.J., and Hattersley, A.T.
(2001). Mutations in the hepatocyte nuclear factor-1beta gene are associated
with familial hypoplastic glomerulocystic kidney disease. Am. J. Hum. Genet.
68, 219–224.
Bjørkhaug, L., Sagen, J.V., Thorsby, P., Søvik, O., Molven, A., and Njølstad,
P.R. (2003). Hepatocyte nuclear factor-1 alpha gene mutations and diabetes
in Norway. J. Clin. Endocrinol. Metab. 88, 920–931.
Bornfeldt, K.E., and Tabas, I. (2011). Insulin resistance, hyperglycemia, and
atherosclerosis. Cell Metab. 14, 575–585.
Borowiec, M., Liew, C.W., Thompson, R., Boonyasrisawat, W., Hu, J., Mlynar-
ski, W.M., El Khattabi, I., Kim, S.H., Marselli, L., Rich, S.S., et al. (2009).
Mutations at the BLK locus linked to maturity onset diabetes of the young
and beta-cell dysfunction. Proc. Natl. Acad. Sci. USA 106, 14460–14465.
Boulting, G.L., Kiskinis, E., Croft, G.F., Amoroso, M.W., Oakley, D.H., Wainger,
B.J., Williams, D.J., Kahler, D.J., Yamaki, M., Davidow, L., et al. (2011). A func-
tionally characterized test set of human induced pluripotent stem cells. Nat.
Biotechnol. 29, 279–286.
Brosius, F.C., 3rd, Alpers, C.E., Bottinger, E.P., Breyer, M.D., Coffman, T.M.,
Gurley, S.B., Harris, R.C., Kakoki, M., Kretzler, M., Leiter, E.H., et al.; Animal
Models of Diabetic Complications Consortium. (2009). Mouse models of
diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2503–2512.
Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying
mechanism. Diabetes 54, 1615–1625.
Bugger, H., and Abel, E.D. (2009). Rodent models of diabetic cardiomyopathy.
Dis. Model. Mech. 2, 454–466.
Byrne, M.M., Sturis, J., Fajans, S.S., Ortiz, F.J., Stoltz, A., Stoffel, M., Smith,
M.J., Bell, G.I., Halter, J.B., and Polonsky, K.S. (1995). Altered insulin secretory
responses to glucose in subjects with a mutation in the MODY1 gene on chro-
mosome 20. Diabetes 44, 699–704.
Campbell, J.M., Nottle, M.B., Vassiliev, I., Mitchell, M., and Lane, M. (2012).
Insulin increases epiblast cell number of in vitro cultured mouse embryos via
the PI3K/GSK3/p53 pathway. Stem Cells Dev. 21, 2430–2441.
Cantley, L.C. (2002). The phosphoinositide 3-kinase pathway. Science 296,
1655–1657.
Chang, C.W., Lai, Y.S., Pawlik, K.M., Liu, K., Sun, C.W., Li, C., Schoeb, T.R.,
and Townes, T.M. (2009). Polycistronic lentiviral vector for ‘‘hit and run’’
reprogramming of adult skin fibroblasts to induced pluripotent stem cells.
Stem Cells 27, 1042–1049.
Chen, G., Gulbranson, D.R., Hou, Z., Bolin, J.M., Ruotti, V., Probasco, M.D.,
Smuga-Otto, K., Howden, S.E., Diol, N.R., Propson, N.E., et al. (2011). Chem-
ically defined conditions for human iPSC derivation and culture. Nat. Methods
8, 424–429.
Cheng, X., Ying, L., Lu, L., Galva˜o, A.M., Mills, J.A., Lin, H.C., Kotton, D.N.,
Shen, S.S., Nostro, M.C., Choi, J.K., et al. (2012). Self-renewing endodermalprogenitor lines generated from human pluripotent stem cells. Cell Stem Cell
10, 371–384.
Cle´ment, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gour-
melen, M., Dina, C., Chambaz, J., Lacorte, J.M., et al. (1998). A mutation in the
human leptin receptor gene causes obesity and pituitary dysfunction. Nature
392, 398–401.
Clocquet, A.R., Egan, J.M., Stoffers, D.A., Muller, D.C., Wideman, L., Chin,
G.A., Clarke, W.L., Hanks, J.B., Habener, J.F., and Elahi, D. (2000). Impaired
insulin secretion and increased insulin sensitivity in familial maturity-onset dia-
betes of the young 4 (insulin promoter factor 1 gene). Diabetes 49, 1856–1864.
Collins, F.S., and Mansoura, M.K. (2001). The Human Genome Project.
Revealing the shared inheritance of all humankind. Cancer 91(Suppl ),
221–225.
Collombat, P., Hecksher-Sørensen, J., Broccoli, V., Krull, J., Ponte, I., Mun-
diger, T., Smith, J., Gruss, P., Serup, P., and Mansouri, A. (2005). The simulta-
neous loss of Arx and Pax4 genes promotes a somatostatin-producing cell
fate specification at the expense of the alpha- and beta-cell lineages in the
mouse endocrine pancreas. Development 132, 2969–2980.
Coppieters, K.T., Wiberg, A., Tracy, S.M., and vonHerrath, M.G. (2012). Immu-
nology in the clinic review series: focus on type 1 diabetes and viruses: the role
of viruses in type 1 diabetes: a difficult dilemma. Clin. Exp. Immunol. 168, 5–11.
Craig, E.A., Stevens, M.V., Vaillancourt, R.R., and Camenisch, T.D. (2008).
MAP3Ks as central regulators of cell fate during development. Dev. Dyn.
237, 3102–3114.
Davies, J.E., Siczkowski, M., Sweeney, F.P., Quinn, P.A., Krolewski, B.,
Krolewski, A.S., and Ng, L.L. (1995). Glucose-induced changes in turnover
of Na+/H+ exchanger of immortalized lymphoblasts from type I diabetic
patients with nephropathy. Diabetes 44, 382–388.
Dhingra, R., and Vasan, R.S. (2012). Diabetes and the risk of heart failure. Heart
Fail. Clin. 8, 125–133.
Ding, Q., Lee, Y.K., Schaefer, E.A., Peters, D.T., Veres, A., Kim, K., Kuper-
wasser, N., Motola, D.L., Meissner, T.B., Hendriks, W.T., et al. (2013a). A
TALEN genome-editing system for generating human stem cell-based disease
models. Cell Stem Cell 12, 238–251.
Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., and Musunuru, K.
(2013b). Enhanced efficiency of human pluripotent stem cell genome editing
through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–394.
Doria, A., Patti, M.E., and Kahn, C.R. (2008). The emerging genetic architecture
of type 2 diabetes. Cell Metab. 8, 186–200.
Driver, J.P., Serreze, D.V., and Chen, Y.G. (2011). Mouse models for the study
of autoimmune type 1 diabetes: a NOD to similarities and differences to human
disease. Semin. Immunopathol. 33, 67–87.
Dymecki, S.M., Niederhuber, J.E., and Desiderio, S.V. (1990). Specific expres-
sion of a tyrosine kinase gene, blk, in B lymphoid cells. Science 247, 332–336.
Ebert, A.D., Yu, J., Rose, F.F., Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A.,
and Svendsen, C.N. (2009). Induced pluripotent stem cells from a spinal
muscular atrophy patient. Nature 457, 277–280.
Edghill, E.L., Flanagan, S.E., and Ellard, S. (2010). Permanent neonatal dia-
betes due to activatingmutations in ABCC8 andKCNJ11. Rev. Endocr. Metab.
Disord. 11, 193–198.
Eiselleova, L., Matulka, K., Kriz, V., Kunova, M., Schmidtova, Z., Neradil, J.,
Tichy, B., Dvorakova, D., Pospisilova, S., Hampl, A., and Dvorak, P. (2009).
A complex role for FGF-2 in self-renewal, survival, and adhesion of human
embryonic stem cells. Stem Cells 27, 1847–1857.
Erceg, S., Ronaghi, M., and Stojkovic, M. (2009). Human embryonic stem cell
differentiation toward regional specific neural precursors. Stem Cells 27,
78–87.
Fajans, S.S., Bell, G.I., and Polonsky, K.S. (2001). Molecular mechanisms and
clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J.
Med. 345, 971–980.
Farooqi, I.S., Keogh, J.M., Yeo, G.S., Lank, E.J., Cheetham, T., and O’Rahilly,
S. (2003). Clinical spectrum of obesity and mutations in the melanocortin 4
receptor gene. N. Engl. J. Med. 348, 1085–1095.Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 787
Cell Metabolism
ReviewFernandez-Zapico, M.E., van Velkinburgh, J.C., Gutie´rrez-Aguilar, R., Neve,
B., Froguel, P., Urrutia, R., and Stein, R. (2009). MODY7 gene, KLF11, is a
novel p300-dependent regulator of Pdx-1 (MODY4) transcription in pancreatic
islet beta cells. J. Biol. Chem. 284, 36482–36490.
Ferrer, J. (2002). A genetic switch in pancreatic beta-cells: implications for
differentiation and haploinsufficiency. Diabetes 51, 2355–2362.
Franks, P.W. (2011). Gene3 environment interactions in type 2 diabetes. Curr.
Diab. Rep. 11, 552–561.
Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage, S.,
Stoffel, M., Takeda, J., Passa, P., et al. (1993). Familial hyperglycemia due to
mutations in glucokinase. Definition of a subtype of diabetes mellitus.
N. Engl. J. Med. 328, 697–702.
Fujikura, J., Nakao, K., Sone, M., Noguchi, M., Mori, E., Naito, M., Taura, D.,
Harada-Shiba, M., Kishimoto, I., Watanabe, A., et al. (2012). Induced pluripo-
tent stem cells generated from diabetic patients with mitochondrial DNA
A3243G mutation. Diabetologia 55, 1689–1698.
Ghosh, S., Golbidi, S., Werner, I., Verchere, B.C., and Laher, I. (2010). Select-
ing exercise regimens and strains to modify obesity and diabetes in rodents:
an overview. Clin. Sci. 119, 57–74.
Gonza´lez, F., Boue´, S., and Izpisu´a Belmonte, J.C. (2011). Methods for making
induced pluripotent stem cells: reprogramming a` la carte. Nat. Rev. Genet. 12,
231–242.
Gruppuso, P.A., Gorden, P., Kahn, C.R., Cornblath, M., Zeller, W.P., and
Schwartz, R. (1984). Familial hyperproinsulinemia due to a proposed defect
in conversion of proinsulin to insulin. N. Engl. J. Med. 311, 629–634.
Haldorsen, I.S., Vesterhus, M., Raeder, H., Jensen, D.K., Søvik, O., Molven, A.,
and Njølstad, P.R. (2008). Lack of pancreatic body and tail in HNF1B mutation
carriers. Diabet. Med. 25, 782–787.
Hambright, D., Park, K.Y., Brooks, M., McKay, R., Swaroop, A., and Nasonkin,
I.O. (2012). Long-term survival and differentiation of retinal neurons derived
from human embryonic stem cell lines in un-immunosuppressedmouse retina.
Mol. Vis. 18, 920–936.
Harwood, H.J., Jr., Listrani, P., and Wagner, J.D. (2012). Nonhuman primates
and other animal models in diabetes research. J. Diabetes Sci. Tech. 6,
503–514.
Hattersley, A.T., and Ashcroft, F.M. (2005). Activating mutations in Kir6.2 and
neonatal diabetes: new clinical syndromes, new scientific insights, and new
therapy. Diabetes 54, 2503–2513.
Haumaitre, C., Barbacci, E., Jenny, M., Ott, M.O., Gradwohl, G., and Cere-
ghini, S. (2005). Lack of TCF2/vHNF1 in mice leads to pancreas agenesis.
Proc. Natl. Acad. Sci. USA 102, 1490–1495.
Hayhurst, G.P., Lee, Y.H., Lambert, G., Ward, J.M., and Gonzalez, F.J. (2001).
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for main-
tenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21,
1393–1403.
Hegele, R.A. (2003). Monogenic forms of insulin resistance: apertures that
expose the common metabolic syndrome. Trends Endocrinol. Metab. 14,
371–377.
Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H., Hinokio, Y., Cockburn, B.N.,
Lindner, T., Yamagata, K., Ogata, M., Tomonaga, O., et al. (1997). Mutation
in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY.
Nat. Genet. 17, 384–385.
Hua, H., Shang, L., Martinez, H., Freeby, M., Gallagher, M.P., Ludwig, T.,
Deng, L., Greenberg, E., Leduc, C., Chung, W.K., et al. (2013). iPSC-derived
b cells model diabetes due to glucokinase deficiency. J. Clin. Invest. 123,
3146–3153.
Ilag, L.L., Tabaei, B.P., Herman, W.H., Zawacki, C.M., D’Souza, E., Bell, G.I.,
and Fajans, S.S. (2000). Reduced pancreatic polypeptide response to hypo-
glycemia and amylin response to arginine in subjects with a mutation in the
HNF-4alpha/MODY1 gene. Diabetes 49, 961–968.
Islam, M.S., and Loots, T. (2009). Experimental rodent models of type 2
diabetes: a review. Methods Find. Exp. Clin. Pharmacol. 31, 249–261.788 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.Isomaa, B., Henricsson, M., Lehto, M., Forsblom, C., Karanko, S., Sarelin, L.,
Ha¨ggblom, M., and Groop, L. (1998). Chronic diabetic complications in
patients with MODY3 diabetes. Diabetologia 41, 467–473.
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A.,
Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011). Modelling
the long QT syndrome with induced pluripotent stem cells. Nature 471,
225–229.
Iynedjian, P.B., Pilot, P.R., Nouspikel, T., Milburn, J.L., Quaade, C., Hughes,
S., Ucla, C., and Newgard, C.B. (1989). Differential expression and regulation
of the glucokinase gene in liver and islets of Langerhans. Proc. Natl. Acad. Sci.
USA 86, 7838–7842.
Jackson, R.S., Creemers, J.W., Ohagi, S., Raffin-Sanson, M.L., Sanders, L.,
Montague, C.T., Hutton, J.C., and O’Rahilly, S. (1997). Obesity and impaired
prohormone processing associated with mutations in the human prohormone
convertase 1 gene. Nat. Genet. 16, 303–306.
Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-promoter-
factor 1 is required for pancreas development in mice. Nature 371, 606–609.
Kahn, C.R. (1994). Banting Lecture. Insulin action, diabetogenes, and the
cause of type II diabetes. Diabetes 43, 1066–1084.
Kahn, C.R., Vicent, D., and Doria, A. (1996). Genetics of non-insulin-dependent
(type-II) diabetes mellitus. Annu. Rev. Med. 47, 509–531.
Kannankeril, P., Roden, D.M., and Darbar, D. (2010). Drug-induced long QT
syndrome. Pharmacol. Rev. 62, 760–781.
Keshet, Y., and Seger, R. (2010). The MAP kinase signaling cascades: a
system of hundreds of components regulates a diverse array of physiological
functions. Methods Mol. Biol. 661, 3–38.
Kida, Y., and Duffield, J.S. (2011). Pivotal role of pericytes in kidney fibrosis.
Clin. Exp. Pharmacol. Physiol. 38, 467–473.
Kim, M.S., Hwang, N.S., Lee, J., Kim, T.K., Leong, K., Shamblott, M.J., Gear-
hart, J., and Elisseeff, J. (2005). Musculoskeletal differentiation of cells derived
from human embryonic germ cells. Stem Cells 23, 113–123.
King, A.J. (2012). The use of animal models in diabetes research. Br. J. Phar-
macol. 166, 877–894.
King, M., Pearson, T., Rossini, A.A., Shultz, L.D., and Greiner, D.L. (2008).
Humanized mice for the study of type 1 diabetes and beta cell function. Ann.
N Y Acad. Sci. 1150, 46–53.
Kroon, E., Martinson, L.A., Kadoya, K., Bang, A.G., Kelly, O.G., Eliazer, S.,
Young, H., Richardson, M., Smart, N.G., Cunningham, J., et al. (2008). Pancre-
atic endoderm derived from human embryonic stem cells generates glucose-
responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26, 443–452.
Krude, H., Biebermann, H., Luck, W., Horn, R., Brabant, G., and Gru¨ters, A.
(1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmen-
tation caused by POMC mutations in humans. Nat. Genet. 19, 155–157.
Kudva, Y.C., Ohmine, S., Greder, L.V., Dutton, J.R., Armstrong, A., De Lamo,
J.G., Khan, Y.K., Thatava, T., Hasegawa, M., Fusaki, N., et al. (2012). Trans-
gene-free disease-specific induced pluripotent stem cells from patients with
type 1 and type 2 diabetes. Stem Cells Transl Med 1, 451–461.
Kulkarni, R.N., and Zisman, A. (2003). Lessons for human diabetes from exper-
imental mouse models. Curr. Diab. Rep. 3, 168–175.
Lee, A.W., and Cox, R.D. (2011). Use of mouse models in studying type 2 dia-
betes mellitus. Expert Rev. Mol. Med. 13, e1.
Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima,M.J., Fasano,
C.A., Ganat, Y.M., Menon, J., Shimizu, F., Viale, A., et al. (2009). Modelling
pathogenesis and treatment of familial dysautonomia using patient-specific
iPSCs. Nature 461, 402–406.
Li, J., Wang, G., Wang, C., Zhao, Y., Zhang, H., Tan, Z., Song, Z., Ding, M., and
Deng, H. (2007). MEK/ERK signaling contributes to the maintenance of human
embryonic stem cell self-renewal. Differentiation 75, 299–307.
Li, L., Fukunaga-Kalabis, M., and Herlyn, M. (2011). The three-dimensional
human skin reconstruct model: a tool to study normal skin and melanoma pro-
gression. J. Vis. Exp. 54, http://dx.doi.org/10.3791/2937.
Cell Metabolism
ReviewLin, S.A., Kolle, G., Grimmond, S.M., Zhou, Q., Doust, E., Little, M.H., Aronow,
B., Ricardo, S.D., Pera, M.F., Bertram, J.F., and Laslett, A.L. (2010). Subfrac-
tionation of differentiating human embryonic stem cell populations allows the
isolation of amesodermal population enriched for intermediatemesoderm and
putative renal progenitors. Stem Cells Dev. 19, 1637–1648.
Luitse, M.J., Biessels, G.J., Rutten, G.E., and Kappelle, L.J. (2012). Diabetes,
hyperglycaemia, and acute ischaemic stroke. Lancet Neurol. 11, 261–271.
Maassen, J.A., Janssen, G.M., and ’t Hart, L.M. (2005). Molecularmechanisms
of mitochondrial diabetes (MIDD). Ann. Med. 37, 213–221.
Mackay, D.J., and Temple, I.K. (2010). Transient neonatal diabetes mellitus
type 1. Am. J. Med. Genet. C. Semin. Med. Genet. 154C, 335–342.
Maehr, R., Chen, S., Snitow, M., Ludwig, T., Yagasaki, L., Goland, R., Leibel,
R.L., and Melton, D.A. (2009). Generation of pluripotent stem cells from
patients with type 1 diabetes. Proc. Natl. Acad. Sci. USA 106, 15768–15773.
Magre´, J., Dele´pine, M., Khallouf, E., Gedde-Dahl, T., Jr., Van Maldergem, L.,
Sobel, E., Papp, J., Meier, M., Me´garbane´, A., Bachy, A., et al.; BSCLWorking
Group. (2001). Identification of the gene altered in Berardinelli-Seip congenital
lipodystrophy on chromosome 11q13. Nat. Genet. 28, 365–370.
Malecki, M.T., Jhala, U.S., Antonellis, A., Fields, L., Doria, A., Orban, T., Saad,
M., Warram, J.H., Montminy, M., and Krolewski, A.S. (1999). Mutations in
NEUROD1 are associated with the development of type 2 diabetes mellitus.
Nat. Genet. 23, 323–328.
Martin, B.C., Warram, J.H., Krolewski, A.S., Bergman, R.N., Soeldner, J.S.,
and Kahn, C.R. (1992). Role of glucose and insulin resistance in development
of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340,
925–929.
Mathis, D., and Benoist, C. (2012). The influence of the microbiota on type-1
diabetes: on the threshold of a leap forward in our understanding. Immunol.
Rev. 245, 239–249.
Matschinsky, F.M., Glaser, B., and Magnuson, M.A. (1998). Pancreatic beta-
cell glucokinase: closing the gap between theoretical concepts and experi-
mental realities. Diabetes 47, 307–315.
McCarthy, M.I. (2010). Genomics, type 2 diabetes, and obesity. N. Engl. J.
Med. 363, 2339–2350.
McLean, A.B., D’Amour, K.A., Jones, K.L., Krishnamoorthy, M., Kulik, M.J.,
Reynolds, D.M., Sheppard, A.M., Liu, H., Xu, Y., Baetge, E.E., and Dalton, S.
(2007). Activin a efficiently specifies definitive endoderm from human embry-
onic stem cells only when phosphatidylinositol 3-kinase signaling is sup-
pressed. Stem Cells 25, 29–38.
Mendel, D.B., Hansen, L.P., Graves, M.K., Conley, P.B., and Crabtree, G.R.
(1991). HNF-1 alpha and HNF-1 beta (vHNF-1) share dimerization and homeo
domains, but not activation domains, and form heterodimers in vitro. Genes
Dev. 5, 1042–1056.
Merkle, F.T., and Eggan, K. (2013). Modeling human disease with pluripotent
stem cells: from genome association to function. Cell Stem Cell 12, 656–668.
Miller, S.P., Anand, G.R., Karschnia, E.J., Bell, G.I., LaPorte, D.C., and Lange,
A.J. (1999). Characterization of glucokinase mutations associated with matu-
rity-onset diabetes of the young type 2 (MODY-2): different glucokinase
defects lead to a common phenotype. Diabetes 48, 1645–1651.
Millioni, R., Puricelli, L., Iori, E., Trevisan, R., and Tessari, P. (2012). Skin fibro-
blasts as a tool for identifying the risk of nephropathy in the type 1 diabetic
population. Diabetes Metab. Res. Rev. 28, 62–70.
Molven, A., Ringdal, M., Nordbø, A.M., Raeder, H., Støy, J., Lipkind, G.M.,
Steiner, D.F., Philipson, L.H., Bergmann, I., Aarskog, D., et al.; Norwegian
Childhood Diabetes Study Group. (2008). Mutations in the insulin gene can
cause MODY and autoantibody-negative type 1 diabetes. Diabetes 57,
1131–1135.
Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos,M.A., Rau, H., Wareham,
N.J., Sewter, C.P., Digby, J.E., Mohammed, S.N., Hurst, J.A., et al. (1997).
Congenital leptin deficiency is associated with severe early-onset obesity in
humans. Nature 387, 903–908.
Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Flu¨gel, L., Dorn,
T., Goedel, A., Ho¨hnke, C., Hofmann, F., et al. (2010). Patient-specific induced
pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363,
1397–1409.Murry, C.E., and Keller, G. (2008). Differentiation of embryonic stem cells to
clinically relevant populations: lessons from embryonic development. Cell
132, 661–680.
Narayanan, K., Schumacher, K.M., Tasnim, F., Kandasamy, K., Schumacher,
A., Ni, M., Gao, S., Gopalan, B., Zink, D., and Ying, J.Y. (2013). Human embry-
onic stem cells differentiate into functional renal proximal tubular-like cells.
Kidney Int. 83, 593–603.
Naya, F.J., Huang, H.P., Qiu, Y., Mutoh, H., DeMayo, F.J., Leiter, A.B., and
Tsai, M.J. (1997). Diabetes, defective pancreatic morphogenesis, and
abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice.
Genes Dev. 11, 2323–2334.
Neve, B., Fernandez-Zapico, M.E., Ashkenazi-Katalan, V., Dina, C., Hamid,
Y.H., Joly, E., Vaillant, E., Benmezroua, Y., Durand, E., Bakaher, N., et al.
(2005). Role of transcription factor KLF11 and its diabetes-associated gene
variants in pancreatic beta cell function. Proc. Natl. Acad. Sci. USA 102,
4807–4812.
Njølstad, P.R., Søvik, O., Cuesta-Mun˜oz, A., Bjørkhaug, L., Massa, O., Bar-
betti, F., Undlien, D.E., Shiota, C., Magnuson, M.A., Molven, A., et al. (2001).
Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl.
J. Med. 344, 1588–1592.
Odom, D.T., Dowell, R.D., Jacobsen, E.S., Gordon, W., Danford, T.W., MacI-
saac, K.D., Rolfe, P.A., Conboy, C.M., Gifford, D.K., and Fraenkel, E. (2007).
Tissue-specific transcriptional regulation has diverged significantly between
human and mouse. Nat. Genet. 39, 730–732.
Ohmine, S., Squillace, K.A., Hartjes, K.A., Deeds, M.C., Armstrong, A.S.,
Thatava, T., Sakuma, T., Terzic, A., Kudva, Y., and Ikeda, Y. (2012). Reprog-
rammed keratinocytes from elderly type 2 diabetes patients suppress senes-
cence genes to acquire induced pluripotency. Aging (Albany, N.Y. Online) 4,
60–73.
Oki, K., Tatarishvili, J., Wood, J., Koch, P., Wattananit, S., Mine, Y., Monni, E.,
Tornero, D., Ahlenius, H., Ladewig, J., et al. (2012). Human-induced pluripotent
stem cells form functional neurons and improve recovery after grafting in
stroke-damaged brain. Stem Cells 30, 1120–1133.
Oliver, M.F., and Opie, L.H. (1994). Effects of glucose and fatty acids on
myocardial ischaemia and arrhythmias. Lancet 343, 155–158.
Onat, D., Brillon, D., Colombo, P.C., and Schmidt, A.M. (2011). Human
vascular endothelial cells: a model system for studying vascular inflammation
in diabetes and atherosclerosis. Curr. Diab. Rep. 11, 193–202.
Osbak, K.K., Colclough, K., Saint-Martin, C., Beer, N.L., Bellanne´-Chantelot,
C., Ellard, S., and Gloyn, A.L. (2009). Update on mutations in glucokinase
(GCK), which causematurity-onset diabetes of the young, permanent neonatal
diabetes, and hyperinsulinemic hypoglycemia. Hum. Mutat. 30, 1512–1526.
Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch,
M.W., Cowan, C., Hochedlinger, K., and Daley, G.Q. (2008). Disease-specific
induced pluripotent stem cells. Cell 134, 877–886.
Pearson, E.R., Velho, G., Clark, P., Stride, A., Shepherd, M., Frayling, T.M.,
Bulman, M.P., Ellard, S., Froguel, P., and Hattersley, A.T. (2001). beta-cell
genes and diabetes: quantitative and qualitative differences in the pathophys-
iology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes
50(Suppl 1 ), S101–S107.
Pearson, E.R., Flechtner, I., Njølstad, P.R., Malecki, M.T., Flanagan, S.E.,
Larkin, B., Ashcroft, F.M., Klimes, I., Codner, E., Iotova, V., et al.; Neonatal
Diabetes International Collaborative Group. (2006). Switching from insulin to
oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl.
J. Med. 355, 467–477.
Pellegrini, G., and De Luca, M. (2010). Human embryonic stem cell-derived
keratinocytes: how close to clinics? Cell Stem Cell 6, 8–9.
Petersen, K.F., and Shulman, G.I. (2006). Etiology of insulin resistance. Am. J.
Med. 119(Suppl 1 ), S10–S16.
Plengvidhya, N., Kooptiwut, S., Songtawee, N., Doi, A., Furuta, H., Nishi, M.,
Nanjo, K., Tantibhedhyangkul, W., Boonyasrisawat, W., Yenchitsomanus,
P.T., et al. (2007). PAX4 mutations in Thais with maturity onset diabetes of
the young. J. Clin. Endocrinol. Metab. 92, 2821–2826.
Polo, J.M., Liu, S., Figueroa, M.E., Kulalert, W., Eminli, S., Tan, K.Y., Aposto-
lou, E., Stadtfeld, M., Li, Y., Shioda, T., et al. (2010). Cell type of originCell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 789
Cell Metabolism
Reviewinfluences the molecular and functional properties of mouse induced pluripo-
tent stem cells. Nat. Biotechnol. 28, 848–855.
Polychronakos, C., and Li, Q. (2011). Understanding type 1 diabetes through
genetics: advances and prospects. Nat. Rev. Genet. 12, 781–792.
Prado, C.L., Pugh-Bernard, A.E., Elghazi, L., Sosa-Pineda, B., and Sussel, L.
(2004). Ghrelin cells replace insulin-producing beta cells in two mouse models
of pancreas development. Proc. Natl. Acad. Sci. USA 101, 2924–2929.
Pramfalk, C., Karlsson, E., Groop, L., Rudel, L.L., Angelin, B., Eriksson,M., and
Parini, P. (2009). Control of ACAT2 liver expression by HNF4alpha: lesson from
MODY1 patients. Arterioscler. Thromb. Vasc. Biol. 29, 1235–1241.
Raeder, H., Johansson, S., Holm, P.I., Haldorsen, I.S., Mas, E., Sbarra, V., Ner-
moen, I., Eide, S.A., Grevle, L., Bjørkhaug, L., et al. (2006). Mutations in the CEL
VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction.
Nat. Genet. 38, 54–62.
Rask-Madsen, C., and Kahn, C.R. (2012). Tissue-specific insulin signaling,
metabolic syndrome, and cardiovascular disease. Arterioscler. Thromb.
Vasc. Biol. 32, 2052–2059.
Rezania, A., Riedel, M.J., Wideman, R.D., Karanu, F., Ao, Z., Warnock, G.L.,
and Kieffer, T.J. (2011). Production of functional glucagon-secreting a-cells
from human embryonic stem cells. Diabetes 60, 239–247.
Robinson, R., Barathi, V.A., Chaurasia, S.S., Wong, T.Y., and Kern, T.S. (2012).
Update on animal models of diabetic retinopathy: from molecular approaches
to mice and higher mammals. Dis. Model. Mech. 5, 444–456.
Robinton, D.A., and Daley, G.Q. (2012). The promise of induced pluripotent
stem cells in research and therapy. Nature 481, 295–305.
Rowland, T.J., Buchholz, D.E., and Clegg, D.O. (2012). Pluripotent human
stem cells for the treatment of retinal disease. J. Cell. Physiol. 227, 457–466.
Schulz, T.C., Young, H.Y., Agulnick, A.D., Babin, M.J., Baetge, E.E., Bang,
A.G., Bhoumik, A., Cepa, I., Cesario, R.M., Haakmeester, C., et al. (2012). A
scalable system for production of functional pancreatic progenitors from
human embryonic stem cells. PLoS ONE 7, e37004.
Semple, R.K., Savage, D.B., Cochran, E.K., Gorden, P., and O’Rahilly, S.
(2011). Genetic syndromes of severe insulin resistance. Endocr. Rev. 32,
498–514.
Shackleton, S., Lloyd, D.J., Jackson, S.N., Evans, R., Niermeijer, M.F., Singh,
B.M., Schmidt, H., Brabant, G., Kumar, S., Durrington, P.N., et al. (2000).
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet.
24, 153–156.
Shapiro, A.M. (2011). State of the art of clinical islet transplantation and novel
protocols of immunosuppression. Curr. Diab. Rep. 11, 345–354.
Shih, D.Q., Dansky, H.M., Fleisher, M., Assmann, G., Fajans, S.S., and Stoffel,
M. (2000). Genotype/phenotype relationships in HNF-4alpha/MODY1: hap-
loinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein
(CIII), lipoprotein(a), and triglyceride levels. Diabetes 49, 832–837.
Shirasawa, S., Yoshie, S., Yue, F., Ichikawa, H., Yokoyama, T., Nagai, M.,
Tomotsune, D., Hirayama, M., and Sasaki, K. (2011). Pancreatic exocrine
enzyme-producing cell differentiation via embryoid bodies from human
embryonic stem cells. Biochem. Biophys. Res. Commun. 410, 608–613.
Siegert, S., Cabuy, E., Scherf, B.G., Kohler, H., Panda, S., Le, Y.Z., Fehling,
H.J., Gaidatzis, D., Stadler, M.B., and Roska, B. (2012). Transcriptional code
and disease map for adult retinal cell types. Nat. Neurosci. 15, 487–495,
S1–S2.
Song, C.Z., Gavriilidis, G., Asano, H., and Stamatoyannopoulos, G. (2005).
Functional study of transcription factor KLF11 by targeted gene inactivation.
Blood Cells Mol. Dis. 34, 53–59.
Søvik, O., Njølstad, P., Følling, I., Sagen, J., Cockburn, B.N., and Bell, G.I.
(1998). Hyperexcitability to sulphonylurea in MODY3. Diabetologia 41,
607–608.
Sproule, D.M., and Kaufmann, P. (2008). Mitochondrial encephalopathy, lactic
acidosis, and strokelike episodes: basic concepts, clinical phenotype, and
therapeutic management of MELAS syndrome. Ann. N Y Acad. Sci. 1142,
133–158.790 Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc.Steck, A.K., and Winter, W.E. (2011). Review on monogenic diabetes. Curr.
Opin. Endocrinol. Diabetes Obes. 18, 252–258.
Steiner, D.F., Tager, H.S., Chan, S.J., Nanjo, K., Sanke, T., and Rubenstein,
A.H. (1990). Lessons learned from molecular biology of insulin-gene muta-
tions. Diabetes Care 13, 600–609.
Stoffel, M., Froguel, P., Takeda, J., Zouali, H., Vionnet, N., Nishi, S., Weber,
I.T., Harrison, R.W., Pilkis, S.J., Lesage, S., et al. (1992). Human glucokinase
gene: isolation, characterization, and identification of two missense mutations
linked to early-onset non-insulin-dependent (type 2) diabetes mellitus. Proc.
Natl. Acad. Sci. USA 89, 7698–7702.
Stoffers, D.A., Zinkin, N.T., Stanojevic, V., Clarke, W.L., and Habener, J.F.
(1997). Pancreatic agenesis attributable to a single nucleotide deletion in the
human IPF1 gene coding sequence. Nat. Genet. 15, 106–110.
Støy, J., Steiner, D.F., Park, S.Y., Ye, H., Philipson, L.H., and Bell, G.I. (2010).
Clinical and molecular genetics of neonatal diabetes due to mutations in the
insulin gene. Rev. Endocr. Metab. Disord. 11, 205–215.
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L., and Zeng, X.
(2010). Efficient generation of functional dopaminergic neurons from human
induced pluripotent stem cells under defined conditions. Stem Cells 28,
1893–1904.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Tan, K.Y., Eminli, S., Hettmer, S., Hochedlinger, K., and Wagers, A.J. (2011).
Efficient generation of iPS cells from skeletal muscle stem cells. PLoS ONE
6, e26406.
Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. (2006). Critical nodes in signal-
ling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96.
Taylor, S.I. (1992). Lilly Lecture: molecular mechanisms of insulin resistance.
Lessons from patients with mutations in the insulin-receptor gene. Diabetes
41, 1473–1490.
Teo, A.K., Windmueller, R., Johansson, B.B., Dirice, E., Njolstad, P.R., Tjora,
E., Raeder, H., and Kulkarni, R.N. (2013). Derivation of human induced plurip-
otent stem cells from patients with maturity onset diabetes of the young.
J. Biol. Chem. 288, 5353–5356.
Texido, G., Su, I.H., Mecklenbra¨uker, I., Saijo, K., Malek, S.N., Desiderio, S.,
Rajewsky, K., and Tarakhovsky, A. (2000). The B-cell-specific Src-family
kinase Blk is dispensable for B-cell development and activation. Mol. Cell.
Biol. 20, 1227–1233.
Thatava, T., Kudva, Y.C., Edukulla, R., Squillace, K., De Lamo, J.G., Khan,
Y.K., Sakuma, T., Ohmine, S., Terzic, A., and Ikeda, Y. (2013). Intrapatient var-
iations in type 1 diabetes-specific iPS cell differentiation into insulin-producing
cells. Mol. Ther. 21, 228–239.
Tirabassi, R.S., Flanagan, J.F., Wu, T., Kislauskis, E.H., Birckbichler, P.J., and
Guberski, D.L. (2004). The BBZDR/Wor rat model for investigating the compli-
cations of type 2 diabetes mellitus. ILAR J. 45, 292–302.
Tiscornia, G., Vivas, E.L., and Izpisu´a Belmonte, J.C. (2011). Diseases in a dish:
modeling human genetic disorders using induced pluripotent cells. Nat. Med.
17, 1570–1576.
Tsigos, C., Kyrou, I., and Raptis, S.A. (2002). Monogenic forms of obesity and
diabetes mellitus. J. Pediatr. Endocrinol. Metab. 15, 241–253.
Vallon, V., and Thomson, S.C. (2012). Renal function in diabetic disease
models: the tubular system in the pathophysiology of the diabetic kidney.
Annu. Rev. Physiol. 74, 351–375.
van Belle, T.L., Coppieters, K.T., and von Herrath, M.G. (2011). Type 1 dia-
betes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91,
79–118.
Velho, G., Froguel, P., Clement, K., Pueyo, M.E., Rakotoambinina, B., Zouali,
H., Passa, P., Cohen, D., and Robert, J.J. (1992). Primary pancreatic beta-cell
secretory defect caused bymutations in glucokinase gene in kindreds ofmatu-
rity onset diabetes of the young. Lancet 340, 444–448.
Velho, G., Petersen, K.F., Perseghin, G., Hwang, J.H., Rothman, D.L., Pueyo,
M.E., Cline, G.W., Froguel, P., and Shulman, G.I. (1996). Impaired hepatic
Cell Metabolism
Reviewglycogen synthesis in glucokinase-deficient (MODY-2) subjects. J. Clin. Invest.
98, 1755–1761.
Vesterhus, M., Raeder, H., Kurpad, A.J., Kawamori, D., Molven, A., Kulkarni,
R.N., Kahn, C.R., and Njølstad, P.R. (2010). Pancreatic function in carboxyl-
ester lipase knockout mice. Pancreatology 10, 467–476.
Vincent, A.M., Callaghan, B.C., Smith, A.L., and Feldman, E.L. (2011). Diabetic
neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 7,
573–583.
Visscher, P.M., Brown, M.A., McCarthy, M.I., and Yang, J. (2012). Five years of
GWAS discovery. Am. J. Hum. Genet. 90, 7–24.
Wang, L., Schulz, T.C., Sherrer, E.S., Dauphin, D.S., Shin, S., Nelson, A.M.,
Ware, C.B., Zhan,M., Song, C.Z., Chen, X., et al. (2007). Self-renewal of human
embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2
receptor signaling. Blood 110, 4111–4119.
Welham, M.J., Storm, M.P., Kingham, E., and Bone, H.K. (2007). Phosphoino-
sitide 3-kinases and regulation of embryonic stem cell fate. Biochem. Soc.
Trans. 35, 225–228.
Winter, W.E., and Schatz, D.A. (2011). Autoimmune markers in diabetes. Clin.
Chem. 57, 168–175.
Wu, K.K., and Huan, Y. (2007). Diabetic atherosclerosis mouse models.
Atherosclerosis 191, 241–249.
Yamagata, K., Furuta, H., Oda, N., Kaisaki, P.J., Menzel, S., Cox, N.J., Fajans,
S.S., Signorini, S., Stoffel, M., and Bell, G.I. (1996a). Mutations in the hepato-
cyte nuclear factor-4alpha gene in maturity-onset diabetes of the young
(MODY1). Nature 384, 458–460.Yamagata, K., Oda, N., Kaisaki, P.J., Menzel, S., Furuta, H., Vaxillaire, M.,
Southam, L., Cox, R.D., Lathrop, G.M., Boriraj, V.V., et al. (1996b). Mutations
in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the
young (MODY3). Nature 384, 455–458.
Yamagata, K., Yang, Q., Yamamoto, K., Iwahashi, H., Miyagawa, J., Okita, K.,
Yoshiuchi, I., Miyazaki, J., Noguchi, T., Nakajima, H., et al. (1998). Mutation
P291fsinsC in the transcription factor hepatocyte nuclear factor-1alpha is
dominant negative. Diabetes 47, 1231–1235.
Yang, Y.M., Gupta, S.K., Kim, K.J., Powers, B.E., Cerqueira, A., Wainger, B.J.,
Ngo, H.D., Rosowski, K.A., Schein, P.A., Ackeifi, C.A., et al. (2013). A small
molecule screen in stem-cell-derived motor neurons identifies a kinase inhib-
itor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713–726.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L.,
Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced
pluripotent stem cell lines derived from human somatic cells. Science 318,
1917–1920.
Zeng, H., Guo, M., Martins-Taylor, K., Wang, X., Zhang, Z., Park, J.W., Zhan,
S., Kronenberg, M.S., Lichtler, A., Liu, H.X., et al. (2010). Specification of
region-specific neurons including forebrain glutamatergic neurons from
human induced pluripotent stem cells. PLoS ONE 5, e11853.
Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced
pluripotent stem cells. Nature 474, 212–215.
Zhou, L., Wang, W., Liu, Y., Fernandez de Castro, J., Ezashi, T., Telugu, B.P.,
Roberts, R.M., Kaplan, H.J., and Dean, D.C. (2011). Differentiation of induced
pluripotent stem cells of swine into rod photoreceptors and their integration
into the retina. Stem Cells 29, 972–980.Cell Metabolism 18, December 3, 2013 ª2013 Elsevier Inc. 791
